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SUMMARY 
The determination of trace amounts of drugs and metabolites in 
biological fluids has proved of immense value in ensuring safer and 
more effective therapy. In recent years HPLC especially in the ion- 
pair mode has become very widely used for drug analysis. Conventional 
theory predicts that the addition of an oppositely charged ion will 
increase the retention of a charged solute on an alkyl bonded silica 
column. This has been confirmed on Hypersil ODS for the beta-blocker 
drug propranolol, using sodium dodecyl sulphate (SDS) as the pairing- 
ion. The mobile phase composition was optimised and a sample 
preparation procedure was developed allowing the determination of 
propranolol down to 0.5 ng/ml plasma. It was found that the retention 
of propranolol and analogues was related to the amount of SDS adsorbed 
onto the surface of the column. 
The use of silica columns for the determination of ionised species 
is less common. A system has been developed allowing chromatography of 
the antidepressant drug chlorpromazine and some metabolites on a silica 
column. The mobile phase was aqueous and contained a pairing-ion, 
heptane sulphonate (HS) which caused solute retention to decrease with 
increasing concentration of pairing-ion. Suitable sample preparation 
procedures allowed the determination of therapeutic levels of the drug 
and two metabolites. An HPLC method using ion-pairing, suitable for 
the determination of therapeutic levels, has also been developed for 
tamoxifen and its desmethyl metabolite. The method utilises a C8- 
silica column and an aqueous mobile phase containing HS. Rather 
suprisingly increasing the concentration of the pairing-ion decreased 
the retention of tamoxifen and metabolites. The three model drugs 
chosen showed the advantages of a systematic study of column choice and 
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of the effect of mobile phase composition on solute retention. 
Ion-pair HPLC operated in the normal phase mode allows detection 
of non UV-absorbing species by utilising a UV-absorbing pairing-ion. 
Experiments using 9-10 dimethoxyanthracene sulphonate (DMAS) indicated 
that this compound was suitable for sensitivity enhancement when using 
solvent extraction, but not when coated as an aqueous stationary phase 
on silica, cyano or diol bonded silica columns. Another important 
application of ion-pair HPLC is the possibility of separating 
enantiomers using chiral pairing-ions. Reverse-phase systems were 
evaluated using some commercially available pairing-ions. 
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CHAPTER 1 INTRODUCTION 
1.1 The need for reliable analytical methods in connection with drug 
safety and efficacy 
The idea that the activity of a drug is dependent upon its 
concentration in whole blood, plasma or serum was first proposed in the 
1940's, for example, with the clinical screening of antimalarials 
[Shannon, 1946]. Since then clinical pharmacologists and clinicians 
have increasingly recognised the utility of measuring blood, serum or 
(more commonly) plasma levels of drugs - this being the best indicator 
available of the concentration at the site of action [Davies, 1973]. 
The study of the rate processes associated with the absorption, 
distribution, metabolism and excretion of a drug is known as 
pharmacokinetics, and involves measuring the levels of a drug and/or 
metabolites in a body fluid (usually plasma or urine) at known 
timepoints after the administration of a dose of the drug. From the 
data thus obtained, various pharmacokinetic parameters can be 
calculated, such as half-life, area under the drug level - time curve 
(bioavailability), time taken to reach peak plasma level, clearance 
rate and apparent volume of distribution. 
There are several reasons why the acquisition of such data is 
valuable [Blanchard, 1979]. Pharmacokinetic analyses provide a means 
for the comparison of different dosage forms of the same drug. A drug 
released too slowly may never reach a sufficiently high concentration 
at the site of action to be effective, or conversely, a rapid rate of 
release may give toxic side effects and then rapidly fall below the 
level necessary for effective therapy. Pharmacokinetic parameters are 
useful in the assessment of absorption and other processes enabling 
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some rationale to be brought into the design of new drugs. The 
determination of pharmacokinetic parameters allows a more dependable 
approach to the aim of achieving clinical effectiveness and provides a 
rational basis for choosing the dosage, release rate and frequency of 
administration. There are many factors such as kidney damage, drug 
interactions, eating habits, enzyme deficiency and induction and liver 
damage [Brodie, 1967] that affect the behaviour of a drug within a 
particular patient and a knowledge of pharmacokinetics can help to 
tailor a dosage regimen to a specific individual (therapeutic 
monitoring). 
This search for correlations between pharmacological or 
toxicological effect and drug concentration in biological fluid 
[Curry, 1977], with the aim of achieving safer and more effective 
therapy [Pribor, 1980] has been the main stimulus to achieving reliable 
analytical methods. Recent advances in analytical technology have 
allowed a massive increase in the amount of pharmacokinetic data 
available even though difficulties are often encountered in quantifying 
pharmacological effects, thus making clinical correlation difficult. 
The task of the analyst is to provide reliable, robustsensitive, 
specific, quantitative assay procedures for the determination of drugs 
and metabolites in body fluids, both during the early stages of a drug 
development programme, and later on in the life of the drug when 
attempts are being made to understand the differences in reaction of 
specific patients to the drug. Metabolites may occur in blood as well 
as in urine, and may themselves be pharmacologically active so that it 
does not suffice to measure only the parent drug. 
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1.2 Methods available for the analysis of drugs and metabolites in 
biological fluids 
The interpretation of drug concentration data is valid only if the 
analytical procedure used measures the drug or metabolite that it is 
intended to measure, and if it does so with acceptable precision and 
accuracy. Improvements in instrumentation have led to a wide array of 
methods allowing differing degrees of sensitivity and specificity to be 
available. Quantification is based on the fundamental relationship 
that the signal produced by the measuring instrument is dependent on 
the concentration (or amount) of the compound being measured. Since 
some loss usually occurs during sample preparation, the calibration 
curve has to be based on values for pure compound 'spiked' into the 
original medium, e. g. control plasma. 
a) U. V. and visible spectrophotometry. 
Conjugated aromatic or w-electron containing species absorb light 
in the ultraviolet (200-400 nm) or visible (400-700 nm) regions of the 
electromagnetic spectrum and the Beer-Lambert law relates the amount of 
light absorbed to the concentration of the absorbing species. The 
absorbance of light by a particular molecule depends upon the 
wavelength of the light, and so a scan of wavelength versus absorbance 
can be made and the wavelength of maximum absorbance determined; 
concentrations can then be obtained by reading at this wavelength in 
e 
order to ach ke optimum sensitivity. 
The sensitivity of a U. V. or visible method obviously depends on 
the absorptivity of the individual compound under investigation, but 
typically the sensitivity for this type of assay [Vessell, 19741 is of 
-10- 
the order of 1-10 Ug/ml of sample. When dealing with biological fluids 
specificity is often poor due to the large number of endogenous 
contaminants of relatively high absorbance present, as well as the fact 
that any metabolites present may well have an absorption spectrum 
similar to the parent drug. Before the advent of some of the more 
sophisticated techniques described later, U. V. and visible spectroscopy 
were the best techniques available for trace analysis, and the range of 
compounds that could be measured was increased by the fact that non- 
absorbing molecules could, if they contained a suitable functional 
group, be reacted with a suitable reagent such that a chromophoric 
derivative was formed. 
b) Luminescence spectroscopy. 
This involves the measurement of light energy emitted by a 
molecule, on returning from the excited state to the ground state. It 
applies to the techniques of both phosphorescence and fluorescence 
(which is more widely used)., For a compound 'to show appreciable 
fluorescence it needs a conjugated system of double bonds held in a 
planar form, and the process is enhanced if suitable functional groups 
such as hydroxy, methoxy, amino or cyano are directly attached to the 
W-electron system. Compounds with no native fluorescence can sometimes 
be converted to fluorescent derivatives by simple chemical 
manipulation such as photochemical induction, oxidation or reduction or 
by the formation of fluorescent derivatives [Bridges, 1976]. 
The structural requirements for phosphorescence are rather 
different from those for fluorescence, even though many compounds 
display both phenomena. Phosphorescence is favoured by excitation from 
a lone pair of electrons and is enhanced by halogens and heavy metal 
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ions wherever substituted. It is rarely observed in solution whereas 
it may be intense in a solid matrix. The most effective form of sample 
preparation is freezing the assay material in liquid nitrogen, although 
more recently techniques for measuring room temperature phosphorescence 
have been introduced. 
From the analytical point of view, both fluorescence and 
phosphorescence assays are sensitive and capable of quantitation in the 
ng to pg range, and can confer some degree of specificity since two 
spectra are involved (ie excitation as well as emission). 
C) Radioderivatization. 
This type of procedure involves reaction of a test substance with 
a suitably radio-labelled reagent eg. tritiated acetic anhydride, such 
that a radioactive product is obtained. The specificity and accuracy 
of the method then hinges on separation of the derivatized drug from 
excess reagent and other unwanted reaction products eg. by TLC or HPLC 
[Scales, 1978]. This type of analysis is not in widespread use 
probably because compounds that can be derivatized can usually be made 
very sensitive to other techniques such as GLC or HPLC (see below). 
d) Electrochemical techniques. 
The most useful branch of electro-analytical chemistry for drug 
analysis purposes is polarography. This involves recording the current 
flow through a small, easily polarizable dropping mercury electrode as 
the potential applied to it (monitored against a reference electrode) 
is steadily increased. The current flow (due to electrochemical 
reduction or oxidation) is dependent on the applied potential, and an 
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S-shaped curve is obtained for each electroactive species in solution. 
The height of the step is proportional to the concentration of the 
electr9active species, and the magnitude of the potential identifies 
the species so that in principle polarography offers a means of both 
qualitative and quantitative analysis. Since its introduction, the 
polarographic technique has been greatly refined and modified. Thus, 
various solid electrodes have been substituted for mercury, primarily 
to extend the working potential range, particularly in the oxidizing 
direction, and a number of different electronic means of modifying the 
applied potential and measuring the current have been devised, 
sometimes leading to greatly improved sensitivity or specificity. 
The sensitivity achieved allows a limit of detection down to -. 10 
ng/ml [Smith, 1976], but the technique often lacks specificity when 
used in bioavailability studies, unless prior separation of drug and 
metabolites is performed. Certain functional groups are particularly 
amenable to polarographic analysis such as nitrosamines [Franklin- 
Smyth, 1975] and N and S oxide [Brooks, 1973 and Beckett 19741. 
e) Ligand methods 
Most ligand techniques involve the preparation of antibodies. 
These are obtained by repeated injection of antigen (drug) into a 
suitable experimental animal such as rabbit, sheep or goat. Smal 1 
molecules such as drugs do not usually elicit antibody formation and 
consequently are injected as conjugates of a protein or polypeptide 
carrier. Although it is the large molecule that stimulates the immune 
response, the antibodies produced usually recognise small parts of the 
antigenic molecule, including, hopefully, some part of the drug moiety. 
The most popular immunological technique for drug analysis is 
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radioimmunoassay (RIA) [Butler, 1976]. In RIA the drug is labelled to 
a high activity and when added will bind to the antibody. On 
subsequent addition of unlabelled antigen (the sample to be assayed) 
competition is established with the radioligand bound. Free and 
ctee antibody bound drug is then separated. The percent inhibition found 
for each biological sample assayed is then compared with known 
standards. 
Problems encountered with RIA include difficulties in preparation 
and purification of antisera, deterioration of antisera on storage and 
metabolite cross-reactivity. Advantages include the fact that once a 
method has been set up large numbers of samples can be assayed in a 
short time, the technique is very sensitive and only small volumes of 
sample are needed, often with no clean up steps. A range of non- 
radiolabels have been used including enzymes, fluorescent and 
chemi I umi nesce"t 1 abel s. A number of systems have been devised (eg. 
E. M. I. T. ) which enable the separation stage to be omitted, thereby 
facilitating automation. 
f) Thin layer chromatography 
TLC involves thin layers of adsorbent physically coated onto glass 
plates, plastic sheets or other suitable inert backing materials. 
Differential adsorption, or less commonly partition (including 
reverse-phase) or ion-exchange have been exploited to obtain elegant 
separations. The technique is simple, versatile, rapid and efficient 
[Stahl, 19691. One major drawback however is the difficulty of 
quantitative assessment of the spots. Measurement of the area of the 
spots by eye, whether under UV light or after using some visualization 
reagent is not very accurate. Removal and extraction of the spots from 
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the plate can be undertaken but this is time consumpting even if, a 
convenient end step is available [Touchstone, 1979]. In recent years 
TLC densitometry in both transmission and reflection mode has become 
well established as a quantitative step. Fluoresence, phosphorescence, 
absorbance, fluorescence quenching and radioactivity are all properties 
that can be evaluated by densitometry and quantitation may be achieved 
in the ng range especially in the fluorescence mode. 
g) Gas liquid chromatography 
GLC has proved a powerful tool for the quantitative analysis of 
drugs and metabolites [Kaye, 19801. The major reason for this is 
probably the fact that GLC was the first technique to combine a rapid, 
efficient separation step with detectors that could be used 'on-line' 
at high sensitivity and with wide applicability. When it was realised 
that metabolites play an important role in the biological action of a 
drug, highly specific techniques such as GLC were adopted in preference 
to less sensitive and less specific techniques such as 
spectrophotometry. 
During a GLC separation the components of interest are partitioned 
between two immiscible phases, one a liquid stationary phase coated on 
to an essentially inert support, the other a gaseous mobile phase. The 
retention characteristics of each compound are influenced by properties 
such as molecular weight, boiling point, vapour pressure and the degree 
of interaction with the stationary phase. A very wide range of 
stationary phases of differing properties are available as well as some 
solid adsorbents such as the Porapak series which do not require a 
liquid phase coating (strictly speaking this is gas-solid chromato- 
graphy). A further advancement in column technology has been the 
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introduction of capillary columns which are much longer and of narrower 
bore than traditional packed columns; capillary columns [Grob, 19781 
are particularly useful in the separation of complex mixtures such as 
environmental samples. 
w 
The sensitivity Of a GLC assay depends to a large degree on the 
response evoked by a particular compound from the type of detector 
used. There are several detectors available, the types of particular 
use in drug-level determination being flame ionisation (FID), electron 
capture (ECD), alkali flame ionisation (AFID) and mass spectrometric 
(MS). 
The FID is probably the most widely used GLC detector since most 
organic molecules cause a response. Compounds eluted from the column 
burn in a hydrogen flame causing a change in current flow between the 
negatively charged flame and a positively charged electrode surrounding 
it. The change in current is proportional to the amount of solute 
being burnt. The detector signal is also proportional to the number of 
carbon atoms in a molecule, but although the response is diminished by 
I the presence of nitrogen, oxygen, sulphur or halogen atoms, the 
detector is generally not very selective. The comparatively high 
sensitivity, wide linear range of response and excellent reliability, 
coupled with its wide range of applications, have made this type of 
detector popular for trace organic analysis, including, to a certain 
extent, in the drug assay field. 
A useful modification of the FID is the AFID. A heated crystal 
such as a rubidium halide is placed in the flame and its presence 
causes an increased response to certain atoms, most notably phosphorus 
and nitrogen. The phosphorus mode has proved useful for pesticide 
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analysis, but for drug determination the nitrogen mode is almost 
invariably used. For a nitrogen-containing drug the AFID is generally 
more sensitive than FID [Bellia, 1978], even if only because the 
response of endogenous co-extracted material is suppressed. The main 
problem with this detector is short crystal lifetime due to poisoning 
by excessive endogenous material, but even so, in the drug-assay field 
many applications of this technique are appearing [Gifford, 1978]. 
The ECD is a very selective, and for some compounds, extremely 
sensitive detector. It utilises a radioactive source to provide a 
constant stream of electrons, collected at a positively charged 
collector electrode. Organic molecules, in the column effluent, which 
contain electrophilic atoms or groups reduce the electron current 
thereby producing the basis for quantitation. Compounds containing 
halogen, nitrogen and carbonyl groups can be effectively measured using 
GC-ECD. The detector response varies enormously between individual 
classes of compounds and although more widely used for trace pesticide 
analysis (since many contain chloride atoms), the sensitivity and 
specificity of this detector has proved useful for trace drug analysis 
[Van den Berg, 19781. Many compounds which do not contain halogen 
molecules can be derivatized (as discussed below) to form halogen- 
enriched molecules, thus rendering them suitable for EC detection at 
low levels. 
The combination of gas chromatography with mass- spectometry (GC- 
MS) results in methodology which is not only very specific but also 
highly sensitive. A mass spectrometer consists of an ion source to 
generate charged species (ion beam), al ion-mass analyzer to separate 
the ions, and a detector to relate the number of analyzed ions into an 
electrical signal. To date most ion beams consist of positive fragment 
I 
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ions generated from the molecule of interest (M) and hopefully 
unfragmented ions (M+) giving-the molecular weight of the compound. 
The foregoing technique is known as electron impact or ionization (EI), 
but a newer ionization procedure, known as chemical ionization (CI) has 
been developed, where neutral M undergoes ionizing collisions with a 
specific set of preformed energetic reagent ions. This ionization can 
occur by proton transfer to give MH+, by hydride abstraction to give 
(M-H)+ or by charge transfer to give M+. Using CI, intense MH+ ions 
can be observed with compounds whose M+ ions, generated by EI, are 
only a small fraction of the total ions. Also, with CI, the reagent 
gas can be the GLC carrier gas, thus obviating the need for separation 
of M from effluent (necessary with EI). 
Increased sensitivity can be achieved by selective ion monitoring 
(SIM) where the ion current at a few, preselected values, 
characteristic of the compound- of - interest, is recorded. Si nce the 
mass spectrometer will separate isotopic species, an internal standard 
that is a stable isotope analogue of the drug can be used, often 
resulting in very good precision. Thus, GC-MS is an extremely powerful 
tool [Baillie, 1978] for the drug analyst. The major drawbacks, 
however, are the high initial outlay for the equipment, the 
requirements of frequent maintenance and highly skilled operation, plus 
difficulties in the interpretation of spectra. 
As mentioned earlier, in connection with other techniques, the 
range of compounds that can be handled by GLC is increased by the use 
of suitable derivatisation procedures. The aim is often to prepare a 
derivative that is more stable than the parent compound, more volatile, 
less thermally labile or less prone to adsorption problems during the 
chromatographic process. Popular derivatization techniques include 
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alkylation, acylation and silylation, the choice of procedure depending 
on the functional groups to be 'blocked'. A further reason for 
derivatization is to render a molecule more responsive to a particular 
type of detector, for example the use of halogen-substituted silylation 
reagents to render alcohols, phenols and carboxylic acids more readily 
detectable with the ECD [Ehrsson, 1978]. Derivatization reactions are 
thus used both to improve the chromatographic properties of a compound 
and to enhance the detector response [Blau, 1977; Knapp, 19791. 
High pressure (performance) liquid chromatography 
In classical liquid chromatography columns were often only used 
for one separation before being discarded, sample application required 
skill and time, solvent flow was under gravity or very low pressures 
and therefore very slow, individual fractions had to be collected and 
assayed separately and finally separations were not very efficient (by 
modern standards) and required several hours. Paper and TLC offered a 
simplified approach and shortened separation times but quantitation was 
still difficult, as was automation and separation times were still 
quite lengthy. As mentioned earlier, the advent of GLC with commercial 
equipment provided the trace organic analyst with separations that were 
faster and better than had been achievable before. However, there were 
still many compounds that could not be handled by GLC due to 
insufficient volality, thermal instability, a tendency to ionise in 
solution, or high polarity or high molecular weight. 
The development of HPLC increased the range of compounds that the 
drug analyst could measure [Snyder, 19741, complementing GLC as well as 
proving more suitable for the analysis of certain compounds not 
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amenable to GLC (see above). Recent advances in technology that have 
contributed include the development of short columns (10-25 cm) of 
narrow diameter (about 5 mm) containing microparticulate (5-10 i1m) 
packings that provide very high efficiency. The pumping of liquids 
through these tightly packed columns, at suitable flow rates, has 
necessitated high inlet pressures, so pumps capable of providing 
continuous reproducible flow rates at several thousand pounds per 
square inch (p. s. i) had to be developed with injectors and connections 
capable of withstanding these pressures. A further requirement before 
the technique became widely applicable to trace analysis was the 
development of sensitve detectors to monitor the column effluent. 
The detectors most widely used in the drug context depend on UV- 
absorption or, less frequently, fluorescence. Of less wide application 
are electrochemical or refractive index monitors. Many drugs absorb in 
the UV-visible region and so the UV detector has proved the most 
valuable. Basically it is an extension of UV spectrometry, mentioned 
earlier, except that a continuous stream of column effluent is 
monitored in a flow cell which needs to be of very low volume (usually 
< 10pl). The obvious limitation of UV detectors is that only compounds 
exhibiting sufficiently strong UV absorption at suitable wavelengths 
can be monitored. The advantages are, reasonable sensitivity, wide 
linear range, baseline stability and the fact that they are non- 
destructive. 
For those compounds which fluoresce, even greater sensitivity has 
been achieved [Twitchett, 19781. As with UV spectrometry, the use of 
HPLC-fluorimetry has led to the development of small volume flow cells. 
in many cases the fluorescence detector is 100-fold more sensitive than 
UV and it is therefore particularly useful in trace analysis. In 
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addition, fluorescence detectors enhance specificity since both 
excitation and emission wavelength define specificity. The 
fluorescence detector, though not lending itself to general use, is a 
powerful tool for a number of applications. 
Many electro-reducible and electro-oxidizable compounds can be 
detected in column effluent by selective electrochemical measurement 
[Kissinger, 19781. Two modes of operation are possible. With the 
first, coulometric detectors electrolysis of solute is taken to 
completion and the response is a function of the number of molecules 
flowing over the electroactive surface. The more common operation is 
amperometric detection, where only a small proportion of solute is 
converted to product and the flux of solute (limited by diffusion) 
across the boundary layer to the electrode surface controls the current 
that is measured. Initially, electrochemical detectors were used in 
the oxidative mode, commonly with a carbon paste or glassy carbon 
electrode. Recently the use of mercury drop electrodes has allowed 
operation in the reductive mode (polarography). Compound types that 
are responsive to electrochemical detection include; phenols, 
mercaptans, aromatic amines, aldehydes and ketones. Limitations to the 
applicability of electrochemical detection are that the mobile phase 
must be electrically conductive, and that the electrodes are easily 
contaminated. The detector is, however, very specific and extremely 
sensitive for certain compound types. 
One detection method that is almost universal is the differential 
measurement of refractive index (RI). Unfortunately, the RI detector 
is relatively insensitive since it measures a bulk property, ie. it 
measures the change in RI when a small amount of sample appears in a 
large excess of solvent. Also, changes in solvent composition and 
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temperature cause baseline drifting problems. 
Detectors less commonly used include transport detectors which 
collect the column effluent on a moving wire which then passes into an 
oven to evaporate the eluent. The wire then moves on to a second 
compartment which vapourises (or oxidizes) any components on the wire 
and these vapours then pass into detectors. The approach traditionally 
used has been with GLC detectors such as flame ionization, electron 
capture or mass spectrometric detectors. The sensitivity of these 
transport detectors is low since not all the material eluted can be 
collected onto the moving wire and another snag is that the eluent must 
not contain involatile salts. The successful coupling of HPLC to MS 
would prove a very powerful tool indeed. Other detectors sometimes 
used include radioactivity monitors and flame photometers. 
As with GLC the range of compounds that can be detected by a 
particular type of HPLC detector can usually be greatly increased by 
the use of suitable derivatization procedures [Lawrence, 1976; Frei, 
19781. Thus HPLC is useful for the analysis of a wide range of 
compounds. 
i) General points concerning choice of method. 
The final choice of an analytical technique to provide the end 
step in a drug assay programme is frequently not easy since there is no 
absolute method of choice. The procedure employed should, however, 
meet the specificity and sensitivity requirements for the individual 
study being undertaken. Factors such as the amount of time and effort 
expended also play a part when analysing biological samples, due to the 
-22- 
fact that it is usually necessary to carry out preliminary manipulation 
of the samples prior to the end step. 
RIA offers advantages since sample preparation is often 
unnecessary and very small sample volumes can be used. However, the 
development of a RIA is a relatively difficult, time consuming and 
sometimes uncertain process since it requires: - 
(a) synthesis of a hapten of the drug which can be coupled to a protein 
to produce the immunogen, 
(b) production of a potent antiserum, 
(c) synthesis of highly labelled drug, 
(d) testing the system for cross-reactivity due to metabolites. 
Although it is sometimes possible to develop specific analyses for 
drugs in biological samples using non-chromatographic methods, 
generally some form of chromatography is necessary. Until recently GLC 
has been the technique most commonly used since it combines highly 
sensitive and possibly selective on-line detectors with high separating 
efficiency. Nowadays more and more assays employ HPLC since it offers 
several advantages over GLC. For example, there is no requirement for 
volatility (only solubility), and as a result highly polar substances 
including zwitterions can be chromatographed underivatized. Another 
advantage is that compounds which are thermally unstable do not present 
a problem with HPLC. Furthermore, the range of options in HPLC is 
greater than for GLC since with the latter the major variables are the 
liquid stationary phase and temperature, whereas with HPLC one can use 
a wide range of mobile phases along with various column types. Sample 
preparation for HPLC can also be simpler in many cases [Foster, 19781 
since aqueous eluents are frequently used for drug and metabolite 
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analysis, occasionally allowing direct injection of biological fluid. 
Over a relatively short period HPLC has thus become the major tool 
used for the measurement of drugs and metabolites in biological fluids. 
The availability of some highly selective, sensitive detectors has 
contributed to this, yet it is the lack of a suitably wide range of 
these that is the greatest drawback. The development of reliable, 
highly sensitive and specific detectors such as coupling MS to HPLC, 
complemented by novel derivatization reactions to enable more compounds 
to evoke a response to the specific detectors available, will probably 
result in the continuing growth in the application of HPLC to trace 
analysis. 
1.3 Sample preparation approaches 
An analytical method for the quantitative analysis of a drug or 
metabolite in a biological fluid usually requires some form of 
isolation procedure. Often the compound of interest is present at very 
low concentrations and the matrix contains numerous endogenous 
compounds, some present at much higher levels than the compound to be 
measured. In human studies, plasma and urine are the most common 
biological matrices although serum, whole blood, saliva, faeces and 
tissue are also used. 
When analysing plasma samples a common means of getting a protein 
free solution is to precipitate the proteins so they can be removed by 
centrifugation. Deproteinization can be undertaken in several ways, 
such as the addition of an acidic reagent eg. trichloroacetic acid 
[Matin, 19751, addition of an organic solvent miscible with water eg. 
acetonitrile [Nation, 1978], heating the biological fluid [Hillcoat, 
-24- 
19761, or use of reagents of high ionic strength. A related technique 
(particularly useful with tissue samples), is digestion of the 
biological material by proteolytic enzymes [Osselton, 1981]. When 
analysing urine many drugs or metabolites may be present as conjugates, 
particularly as glucuronides or sulphates, and these are seldom 
amenable to solvent extraction. Although there are some examples (eg. 
Mrochek, 1974) where conjugates have been chromatographed directly by 
HPLC, it is more common to hydrolyse them, either enzymatically or 
using acid, to release the actual drug or metabolite. 
Processing steps for biological fluids subsequent to those 
mentioned in the preceding paragraph are often similar for plasma (or 
serum and whole blood), urine or tissue homogenates. There are some 
examples of direct injection of urine or plasma onto HPLC columns, 
usually with a pre-column to protect the analytical column [Forster, 
1978] but it is much more common to perform some kind of extraction 
procedure fi rst. The most commonly used extraction procedures are 
based on liquid-liquid extraction methods using a volatile organic 
solvent not miscible with water [Jones, 1976]. If the compound to be 
extracted is ionizable (as is usual with drugs) then the pH of the 
biological medium is adjusted so that the solute is in its unionized 
form (obviously not necessary with neutral molecules) such that it will 
preferentially partition into the organic solvent. The usual approach 
is to use the least polar solvent that will give quantitative extra- 
ction of solute, thereby aiming to minimize the amount of endogenous 
material co-extracted. By altering the pH, the solute may then be 
'back-extracted' into an aqueous phase and subsequently re-extracted 
into an organic solvent in the hope of carrying through reduced amounts 
of extraneous material. A useful variant when dealing with very polar 
materials such as zwitterions (ionized over a wide pH range) is to use 
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an ion-pair extraction, discussed in more detail later (see section 
1.4c). 
When drugs cannot be made to partition efficiently into water- 
immiscible solvents, liquid-solid methods can prove useful [Bye, 1978]. 
The approach typically entails retaining the material of interest on a 
solid support, eluting as much potentially interfering material as 
possible, then collecting a fraction containing the solute of interest, 
still leaving some unwanted endogenous material adsorbed on the solid 
support. Various solid supports have been tried (usually as a column 
or cartridge) including alumina, charcoal, XAD resins, ion-exchange 
resins, silica gel and recently ODS-silica [Bennett, 19771. The choice 
of approach can be logical, based on the separation mechanism chosen 
viz, adsorption, partition or ion-exchange, but these processes cannot 
necessarily be thought of as being the sole mechanisms operative [Reid, 
19761. There is always the danger that a small amount of solute may be 
irreversibly retained, perhaps significant when dealing with very low 
levels. Another disadvantage with solid adsorbents is batch-to-batch 
reproducibility, but one distinct advantage when handling large numbers 
of samples is the possibility of automation, - commercial equipment is 
becoming available. 
Once a drug or metabolite has been extracted into an organic 
solvent, some form of drying down step is usually employed, so that the 
residue can be redissolved in a suitable medium (eg. HPLC mobile phase 
or solvent suitable for GLC injection). Losses can easily occur during 
this step, for example by creeping over the walls of vessels, 
adsorption of a dried down extract onto glassware, or simply because 
the compound was too volatile under the conditions used [Scales, 1980]. 
Reconstituting the extracts from say, 1 ml of plasma, into 100 Ul of a 
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suitable solvent provides a concentration factor useful in trace 
analysis. Since losses will occur at most stages of sample preparation 
it is common practice to 'spike' internal standards as early in the 
procedure as possible, though in some circumstances the use of internal 
standards may not be advantageous [Curry, 1978]. 
A useful method of minimizing sample work-up for HPLC is the use 
of column-switching techniques [Paanakker 1981]. The sample is 
injected onto a pre-column of the same packing material as the 
analytical column, but only a small fraction containing analyte and 
internal standard is allowed to enter the main column; the rest of the 
sample is diverted to waste. Compounds of interest are then eluted. 
Other less comonly used clean-up procedures, not discussed in detail 
here, include the use of TLC and freeze-drying. 
There are then, many options available, but the complexity of the 
sample preparation needed will depend on several factors, such as the 
nature of the biological material to be analysed, the chemical nature 
and levels of compound to be determined and perhaps, most important of 
all, the sensitivity and specificity of the end step. If the 
extraction and clean up steps are efficient, then the detection and 
determination are greatly simplified. 
1.4 Theory of HPLC 0 
a) Basic concepts of chromatographic retention. 
Chromatography is a common name for methods which involve the 
separation of two or more compounds by distribution between two phases, 
one a fixed (stationary phase) and the other a moving (mobile) phase. 
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For separation to occur the so-called stationary phase must have a 
differing ability to retard the various components being carried 
through by the mobile phase. The various forms of chromatography are 
generally named according to the nature of the two phases used, and 
although in this brief description HPLC is the technique of interest, 
much chromatographic theory is common to all forms of chromatography. 
The time that elapses between injection of a solute onto a column 
and elution of this solute from the column is called the retention time 
t, and the time taken for a so-called unretained solute to elute 
R 
(often shown by a refractive index peak) is termed tA convenient 
0 
measure of retention is given by the phase capacity ratio kI. 
where; k' = tR - to 
to 
For a given column and eluent k' is -independent of column dimensions 
and flow, rate and is therefore a useful parameter. The spreading of a 
solute band as it moves down the column is expressed in terms of the 
number of theoretical plates (N) to which the column is equivalent, and 
this is given by; 
N= 16 r+ p or = 5.54 t (2) 1 I-D F R 
tW3, 2 
where tw is the time equivalent to- the width of the peak at its base 
and tw1/2 is the time equivalent to the width of the peak at half its 
height. 
'Theoretical plates' is. a concept adapted from distillation theory 
and although meaningless in itself it is the most common term used to 
express the efficiency of columns. The expression is very useful for 
comparisons: - the higher the N value the better the column. 
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b) Different modes of HPLC. 
There are several modes of HPLC differing only in the nature, 
composition and structure of the stationary phase, and in the nature of 
the molecular forces that act on the solute within the mobile and 
stationary phases. Though considered separately, there is some overlap 
of these different modes and in an HPLC system more than one separation 
mechanism can be contributing to the chromatographic behaviour 
observed. The selection of the best mode of operation for a particular 
separation is difficult and often more than one approach will provide 
satisfactory results. 
Liquid-solid or adsorption chromatography is most commonly carried 
out using porous silica as the adsorbent, although alumina and carbon 
have also been used. Separation is based on selective adsorption, of 
components onto the active sites at the surface of the adsorbent, 
hydroxyl groups in the case of silica. Adsorption can be thoughtof as 
competition for these adsorption sites by different molecules, 
beginning with eluent components [Snyder, 1968]. Thus, if a mobile 
phase consists of a small proportion of a polar solvent (say methanol) 
in a non-polar one, as is common, then the more polar component is 
adsorbed onto the active sites, and is then competitively and 
reversibly replaced by solute molecules until the solute is eluted from 
the column. Applications of adsorption chromatography for HPLC are 
wide-ranging, but in general the technique is used for the separation 
of non-polar or moderately polar molecules. In the trace drug analysis 
field, adsorption chromatography is less common, because with polar 
drug molecules and particularly with drug metabolites, very long 
retention times are often obtained. A problem characteristic of 
adsorption systems is the practical difficulty in maintaining exactly 
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the activity of the surface, leading to some irreproducibility of 
retention times. 
Liquid-liquid partition chromatography (LLC), first described by 
Martin and Synge in 1941, depends upon the differential distribution of 
compounds between two immiscible liquids, one a stationary phase, the 
other a mobile phase. The stationary phase is mechanically held onto 
an essentially inert support material, the mobile phase is saturated 
with stationary phase so as not to strip it from the column, and the 
system needs thermostatting. A wide range of liquids can be used as 
stationary phases but there are only two categories of LLC. In normal- 
phase LLC the stationary phase is polar with respect to the mobile 
phase, and with reverse-phase LLC the converse is true. Support 
materials should be inert and have a large pore volume. LLC is not 
widely used for trace drug analysis due to the practical difficulties 
associated with it, such as maintaining the phase ratios and initial 
coating of the supports (discussed in more detail later in connection 
with normal phase ion-pair chromatography). 
With ion-exchange chromatography (IEC) separation occurs as a 
result of competition between solute ions and ions in the eluent for 
oppositely charged sites on the stationary resin. The packing 
materials therefore possess charge-bearing functional groups. Organic 
resin materials have been used (as is common in classical IEC under 
gravity) despite suffering the disadvantages of poor mass transfer 
characteristics, swelling in solvents and compressibility at high 
pressures. More recently bonded phase particles based on a silica 
matrix have been developed. Although IEC is appropriate for ionic 
species (applicable to many drugs), it has not been widely used for 
trace drug analysis, since in general IEC columns are less stable, less 
-30- 
efficient and less reproducible than other types of HPLC columns. Ion- 
pair chromatography (IPC) in particular, is much more widely used for 
trace drug analysis (as is discussed later in section 1.5), though IEC 
has seen widespread use for amino acid analysis and the analysis of 
nucleotides. 
Size-exclusion or gel-permeation chromatography (GPC) separates 
molecules by size, separation occurring because molecules of different 
sizes have differing abilities to permeate into pores in the column 
particles, large molecules therefore eluting first. GPC is extensively 
used for protein and polymer separations and molecular weight 
distributions, but is not generally applicable to trace drug analysis 
since the molecules are too small. 
Bonded phase chromatography (BPC) is probably the most widely used 
mode of HPLC operation [Colin, 19771. Most bonded phases in current 
use are based on silica and are prepared by reacting surface silanol 
groups with organic molecules to provide a modified surface. The most 
popular packings are those where alkyl chains of different lengths [C18 
is the most common], are bonded onto silica to provide a non-polar 
surface for use in reverse phase (RP) separations. Other groups have 
been reacted to provide polar bonded silicas (for normal phase 
operation), such as diol, thiol, nitro, amino and cyano (which can be 
used either in normal phase or RP operation) as well as other RP 
packings such as phenyl-bonded silica. One advantage of chemically 
bonded phases is that they are more stable than LLC columns and do not 
require thermostatting, or pre-saturation of the mobile phase. In 
practice it is possible to cleave off the bonded phase if conditions 
are too acidic or too alkaline (the pH working range is approximately 
2.5 - 7.5). The mechanism of RP HPLC is not absolutely clear, though 
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it is thought that the hydrophobic surface extracts the more lipophilic 
component of the eluent to form an organic rich layer at the surface 
and then a partition process takes place [Knox, 19751. For the 
determination of trace levels of drugs and metabolites in biological 
fluids, RP operation has become the most common approach [Meffin, 
19801. Most drug metabolites are more polar than the parent drug and 
since in RP operation the more polar molecules elute first, this mode 
of operation is favoured. With normal-phase chromatography eg. on 
silica, many metabolites are too well retained, so that peaks suitable 
for quantitation are not obtained. Another advantage of using HPLC 
operated in the RP mode is that the eluents used are aqueous, sometimes 
permitting direct injection of biological fluid (as mentioned earlier 
in section 1.2i). 
Many drug and drug metabolite molecules contain very polar 
functional groups that are ionizable which often makes them very 
difficult to chromatograph efficiently. On RP columns they are 
completely ionized over the working pH range (2.5 - 7.5) and thus not 
retained, whereas, using straight phase adsorption methods high solute 
retention and poor peak shape are observed. The addition of a suitable 
molecule of the opposite charge (termed the pairing-ion) has provided a 
means of chromatographing many ionic species satisfactorily [Tomlinson, 
1978 and 19831 and is currently in widespread use in the trace drug 
analysis field. 
C) Ion-pair extraction in relation to the selection of ion-pair HPLC 
conditions. 
Ion-pair extraction techniques have long been used for the 
extraction of ionizable compounds from aqueous phases (such as plasma 
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or urine) into organic solvents [Schill 1974]. In its simplest form 
the extraction is represented by; 
B+ aq + P-e4zg# (BP) org (3) I'll 
where B is the protonated form of the base (B) that it is desired to 
extract, P is the anion of the acid used as the pairing ion, and the 
subscripts aq and org refer to the aqueous and organic phases 
respectively. Obviously the roles of the anion and cation can be 
reversed. The extraction constant for this process E is defined 
BP 
by; 
E' [BP]org BP 'ý 
[B+]aq [P-]aq 
(4) 
The distribution ratio for B between the two phases is given by; 
D B+ : -' [BP]org 
[B+]aq (5) 
or 
D B+ =E BP [P-]aq (6) 
From (6) it can be seen that the concentration of the pairing ion 
affects the distribution ratioik of B, so that the choice of a suitable 
pairing-ion and itý concentration provides a simple means of 
controlling the extraction of B. 
In many cases the ions or extracted ion-pair complex participate 
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in other equilibria. Processes involving ions in the aqueous phase 
such as protolysis, association, or micelle formation will tend to 
reduce the extraction yield. Conversely, other equilibria occurring in 
the organic phase, such as dimerization or dissociation of the ion-pair 
complex, will tend to improve the extraction yield. The influence of 
side reactions on the distribution ratio D is accounted for by the 
B+ 
use of the conditional extraction constant E* where; 
BP 
D E* [P-]aq B+ BP (7) 
The conditional extraction constant is given in a form that is 
experimentally useful by; 
c BP org 
E* = (8) 
BP c B+aq CPaq 
where C is, the total molar concentration of B extracted into 
BPorg 
an organic phase as an ion-pair with PC and C are the 
+ B+aq P-aq 
total concentration of B and P in the aqueous phase. The 
conditional extraction constant is related to the stoichiometric 
extraction constant referred to in (4) by the use of a-coefficients, 
E* =EBP BP BP (9) 
where the values of a increase from unity when side reactions begin to 
occur. 
The magnitude of the extraction constant depends on the properties 
of the ions B and P the concentration of P and on the nature 
of the organic solvent used for the extraction. For a particular 
compound (B in this case) the extraction constant increases with 
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increasing pairing ion concentration. The structure of the pairing ion 
affects the extraction constant. The effect of organic anions, for 
example, usually increases in the series carboxylate < sulphonate < 
sulphate and increasing the number of alkyl groups as a rule causes an 
increase in the extraction constant [Schill, 1977]. The extraction 
constant is also affected by the polarity and hydrogen bonding 
properties of the organic solvent used for extraction. Strongly 
hydrogen bonding solvents such as alcohols are good extractants for 
ion-pairs, but they are not as selective as weakly hydrogen bonding 
solvents such as dichloromethane and chloroform. The ion-pair complex, 
though electrically neutral, will often behave as a polar organic 
molecule, so that low polarity solvents such as carbon tetrachloride or 
hexane, give low extraction yields. 
For drug determinations in biological fluids, ion-pair extraction 
may be used as a clean up step for acids and bases that are otherwise 
difficult to partition into an organic phase. A useful extension of 
the technique is the possibility of using a UV absorbing or fluorescent 
pairing-ion to enhance the detection of an otherwise unresponsive 
molecule (discussed more fully later in section 3.4). When deal ing 
with biological materials, ion-pair extraction followed by UV or 
florescence detection can be difficult at low levels due to proteins 
interfering with the extraction and also lack of selectivity giving 
high blanks [Westerlo"nd, 1973a]. 
A logical extension to ion-pair extraction studies is the use of 
IPC where, as with all forms of chromatography, one phase is stationary 
and the other mobile. IPC can be carried out in either the normal or 
RP mode, but in both cases the pairing-ion is added to the aqueous 
phase. Using normal-phase operation then, the stationary phase is an 
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aqueous solution of pairing-ion coated onto a suitable support. In 
this case, chromatographic retention, as represented by k' is related 
to the extraction constant by; 
kl = Vs 
Vm E BPIP-]aq 
(10) 
where Vs/Vm is the phase volume ratio of stationary and mobile phase. 
In the case of RP -IPC the pairing-ion is present in the mobile phase, 
and k' is given by; 
Vs E BP[P-]aq 
Vm (11) 
'n Equations (10) and (11) describe the relatiOShip between A 
chromatographic retention and the extraction constant in the absence of 
side reactions. If these do occur then E* and Cf rom (8) can 
BP p- 
be substituted for E and [P laq. 
BP 
Even so, equations (10) and (11), or the modifications to allow 
for side reactions, merely describe the relationship between 
chromatographic retention and extraction constants in its simplest 
form. Reasonable agreement between retention observed and that 
predicted from extraction data has been shown [Eksborg, 1973a]. 
However, in recent years doubt has arisen as to whether the equilibrium 
implied by (3) adequately describes IPC under all conditions. IPC can 
be sub-divided in several ways, rather than just the simple distinction 
between normal and RP operation given so far, and particularly in the 
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case of RP IPC, several other models have been used to describe the 
behaviour observed. This will be discussed later (Chapter 4). 
1.5 The application of ion-pair HPLC to the determination of drugs and 
metabolites in biological fluids 
The popularity of IPC for the analysis of drugs and metabolites is 
demonstrated by the large number of examples published in the 
literature. Although it is sometimes possible to base the choice of 
chromatographic conditions on the results obtained from batch 
extractions, chromatographic test runs are often a more convenient way. 
When attempting to design an IPC system it is necessary to decide 
whether to use a normal or RP system. Using a normal phase system it 
is easy to vary selectivity by changing the organic (mobile) phase 
composition, and it is also possible to enhance the detector signal by 
using a UV-absorbing or fluorescent pairing-ion. Reverse phase 
operation though does not require a mechanically held (less-stable) 
stationary phase. Solvent strength is easily altered by changing the 
concentration of pairing-ion, and aqueous samples can be injected 
directly. Although there are many examples of mechanically held non- 
polar liquids as the stationary phase [Johansson, 1978], it is much 
more common nowadays to use RP columns such as C or C silica. 
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The selection of conditions for an IPC separation is complicated 
by the fact that there are so many variable parameters eg. nature and 
concentration of pairing ion, mobile phase composition, pH, 
temperature, ionic strength, stationary phase (and support if 
mechanically held) and competing ion concentration. The design of an 
ion-pair separation based on the use of a RP bonded column is further 
complicated by the fact that the underlying mechanism of separation is 
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the subject of much debate (discussed later in sections 3.2 and 3.3). 
However, even though IPC in its various modes cannot be regarded as 
well understood, much experimental data have been explained in terms of 
the simple equations mentioned so far, or in terms of the more 
complicated models discussed later. Whatever the theoretical 
shortcomings are, the flexibility of IPC offers the analyst parameters 
that can be altered with the aim of achieving reproducible, efficient 
separations. The important point in practical terms is to try to 
understand how the factors controlling retention [Gloor, 1977] can be 
used to provide the separation desired. 
1.6 Detection limits in HPLC and attempts to improve them 
The main limitation to the application of HPLC to trace organic 
analysis, lies in the detection system. The most commonly used 
detectors are adaptions of the classical UV spectrophotometer, usually 
with variable wavelength facilities. Many compounds of interest do not 
have sufficiently strong UV absorption to enable their determination at 
the levels required except perhaps at wavelengths below 220nm. 
Detectors that are universally applicable (such as RI) can be tried, 
but for trace drug analysis they almost always lack the sensitivity 
required, and other approaches must therefore be attempted. 
a) Specific detectors and derivatization reactions 
If the compound of interest is amenable to specific detectors such 
as fluorimetric or electrochemical detectors then the problem of 
sensitivity may be overcome. If the compound has little native 
fluorescence or UV absorbance, by carrying out selective 
derivatization, either pre-column or post-column, the problem may also 
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be overcome [Frei, 19781. Both of these procedures require a 
functional group that can be reacted and a suitable derivatization 
procedure. Pre-column derivatization, carried out off line, usually 
requires elimination of excess reagent prior to injection onto the 
chromatograph. Reagents in common use include dansyl chloride and o- 
phthalaldehyde. Pre-column derivatization can sometimes be used not 
only to increase the detection signal of a compound, but also to aid 
the initial extraction of a very polar compound from the biological 
matrix [Reid, 1981b]. The derivatization procedure does not necessarily 
require the addition of chemical reagents: for example, tamoxifen and 
two metabolites can be irradiated with UV light to form highly 
fluorescent products prior to their application to an HPLC column. 
Pre-columderivatization sometimes tends to be less than quantitative 
and may degrade the solute of interest, thus producing several peaks. 
Post-column derivatization is also feasible though it is not 
without technical problems. These include restrictions on the mobile 
phase so as not to interfere with the reaction, the probability of 
band-spreading and the need to use derivatization reagents that either 
are not detected under the same condition as the derivatized sample, or 
can be easily removed. The classical example of a post-column reactor 
is the ninhydrin reaction used in amino acid analysis. For each post- 
column reactor there will be optimum operating parameters for 
temperature, flow rate, reagent concentration and time and each must be 
studied in order to obtain the most effective assay conditions. 
b) Enhancement of detection using a UV absorbing or fluorescent 
pairing-ion. 
A very important feature of ion-pair extraction procedures is that 
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they can be used to increase sensitivity to low or non-UV absorbing or 
non-fluorescent molecules. This is achieved using a pairing-ion that 
is highly absorbant or highly fluorescent so that the resultant ion- 
pair complex itself is highly absorbant or fluorescent. For example, 
propantheline in human plasma has been determined by ion-pair extra- 
ek, U 
ction with DMAS [Westlond, 1973b]. It should be noted that the 
A 
determination of drugs or metabolites in biological fluids by ion-pair 
extraction will still be subject to interferences from endogenous 
material. 
Ion-pair extraction as a post-column 'derivatization' system has 
been described [Frei, 1979] for the fluorimetric determination of 
amines. The detection system is based on fluorescent ion-pair 
formation between amine drugs and DMAS. A micro extraction technique 
was used to separate the ion-pair complex from excess reagent and band 
broadening was less than 20%. 
The use of a pairing-ion to increase the detector signal can also 
be used in IPC when operated in the normal phase mode. The pairing-ion 
is always added to the aqueous phase, which is the mobile phase with RP 
operation and therefore a UV or fluorescent pairing-ion cannot be used 
as it would 'swamp' the detector signal. However, in normal phase 
operation, the pairing-ion is coated as an aqueous solution onto a 
support and only elutes from the column (under ideal conditions) when 
paired with solute ions. Cationic compounds have been determined using 
picrate [Santi, 19751 or naphthalene sulphonate [Crommen, 19771 as 
pairing-ion, and anions have been detected using dimethyl 
protriptylenium [Ersborg, 1973b]. The technique has the disadvantages 
of a mechanically held stationary phase (loading requirements and 
maintenance of phase volume ratio). The value of increasing detector 
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signal using the normal phase approach will be discussed later (see 
section 3.4). 
Normal phase IPC thus has a particular advantage over the more 
commonly used RP mode of operation, by allowing the detection at low 
concentrations of compounds of low UV or fluorescent response. 
1.7 Separation of enantiomers by HPLC. 
A very exacting test of a chromatographic technique is the 
separation of enantiomers (non-superimposable mirror images). The 
physical and spectral properties of enantiomers are virtually 
identical, except for their interaction with plane-polarized light, 
which they rotate equally but in opposite directions. The foregoing 
statement is true only in the absence of other optically active 
(chiral) reagents. With chiral reagents two enantiomers may have 
different affinities or rates of reaction. Attempts to separate 
(resolve) two enantiomers therefore, usually involve$ the setting up of 
a chiral environment. 
Until recent years two main methods have been used. The first 
involves the use of optically active derivatization reagents to produce 
diastereomeric mixtures. For example, d- and 1- propranolol have been 
reacted with the chiral reagent N-trifluroacetyl-l-prolylchloride to 
produce diastereoisomers that can be separated by RP HPLC on a C8 or 
C18 bonded column. Many such derivatives have been prepared for GLC 
V [Halpern, 19771, although HPLC offers an adantage over GLC for A 
preparative work, in that quantitative recovery of enantiomers is 
possible. 
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The second technique involves the, preparation of a ; chiral 
stationary phase, and the stereoselective sorption of enantiomers onto 
it. For example, Hara (1979) prepared a chiral amide-bonded silica gel 
for the separation of optically active amino acid derivatives. 
It should be possible-to adapt IPC for the direct resolution of 
enantiomers by using an optically active pairing-ion, in the eluent. 
Both the optically active compound of interest and the chiral, pairing- 
M ion probably need the asMetric centre to, be in close proximitty to A 
the ionizable group, -, and need to contain functional groups-large enough 
for some sort of steric interaction to occur. Another requirement is 
that two ions must actually associate in some way, a process that does 
not always occur under some conditions used for chromatography. The 
concept however, is sound and Pettersson (1981) has recently 
demonstrated its application to the separation of propranolol and two 
related drugs. 
1.8 Model compounds 
(a) Propranolol 
Propranolol (1-isopropylamino-3-(naphth-1-yloxy) propan-2-ol), 
below; 
O. CH 2'CH. CH 2*NH. CH(CH 3)2 
UH 
is a beta-adrenergic blocker and has been widely used An the treatment 
of - angina ýpectoris, cardiac arrhythmias., 
hypertension and 
thyrotoxicosis. The major metabolites include 4-hydroxypropanolol and 
napthoxylactic acid [Bond, 1967; Easterling,, 1979]., the former is 
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thought to be active, though all of the s-blocking activity has been 
reported as due to the parent drug [Cleveland, 1975]. Recently a long 
acting, slow release formulation of propranolol (inderal L. A. ) has been 
in use. Measurement of very low levels of the drug in plasma thus 
allows all these formulations to be monitored. Previous methods for 
the determination of propanolol in plasma or serum have included; 
fluorimetry [Shand, 1970], GLC following derivatization [DiSalle, 
1973], GLC-mass fragmentography [Walle, 1975] and HPLC fluorimety 
[Nygard, 1979, Jatlow, 1979, Taburet, 1979, Mackichan, 1980, Lo, 1980]. 
Sample preparation for mos t of these methods has involved solvent 
extraction from alkaline plasma (the pKa for propranolol is about 9). 
(b) Chlorpromazine. 
There are notorious difficulties in assaying blood for the 
antidepressant drug chlorpromazine (2-chloro-10-[3-dimethylamino- 
propyllphenothiazine, below) and the metabolites of interest, notably 
SN 
0 
Cl 
N 
ýCHI)ý 
N (CH 
chlorpromazine sulfoxide aný 
ýspecially 7-hydroxychloropromazine. Such 
metabolites as well as the parent drug may occur in vivo in a 
demethylated form or as an amine oxide which may revert to or even 
arise from the amine in vitro. Even if reliable GLC separation is 
achieved, there may be analytical problems due, for example, to 
adsorption onto glass or to photodecomposition. 
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It was because chlorpromazine sulfoxide and derivatized 7- 
hydroxychlorpromazine ran poorly when published GLC conditions were 
applied that attention was turned to the HPLC approach, encouraged by 
reported. pilot work with a silica column [Watson, 1979]. 
For chlorpromazine and its sulphoxide, the primary extraction from 
plasma requires a low-polarity solvent, so that amine oxides, which 
could revert to their parent compounds during the sample preparation 
procedure, are not co-extracted. Extraction of the 7-hydroxy 
metabolite however, calls for a fairly polar solvent, at a pH not so 
high that the poorly extractable phenate ion is formed [Curry, 1976]. 
Two independent extraction procedures were thus called for. 
C) Tamoxifen 
Tamoxifen (trans-l-(p-0 dimethylaminoethoxyphenyl)-1,2- 
diphenylbut-l-ene) is an anti-oestrogenic agent widely used in the 
treatment of breast cancer [Mourisden, 1978]. The structure of 
tamoxifen is shown below with R= CH ,R=H 1-32 
CH 3- N-CH 2-CH -0 12 
K1 
114 
A TLC study using C tamoxifen indicated that aromatic 
hydroxylation to give 4-hydroxytamoxifen (R H, R OH), was 
12 
the major metabolic pathway [Fromson, 1973]. More recent work [Adam, 
19791, has shown that the major serum metabolite is N- 
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desmethyltamoxifen (R H, R H). The latter group used TLC 
112 
separation, followed by UV irradiation of the plate to convert drug and 
metabolite into highly fluorescent products suitable for measurement by 
densitometry in situ. Unequivocal identification of the N-desmethyl 
metabolite was shown by GC-MS. Another study [Daniel, 1979], based on 
the GC-MS determination of tamoxifen and 4-hydroxytamoxifen, showed 
that patients given 20 mg of tamoxifen daily reached a peak drug level 
-1 
of 150-250 ng ml and that the levels of 4-hydroxytamoxifen did not 
-1 
rise above 8 ng ml 
An HPLC method for the determination of tamoxifen and its N- 
desmethyl and 4-hydroxymetabolites in human plasma has been described 
by Golander 1980 (an improvement on an earlier method, Mendenhall, 
1978). This method required irradiation of plasma extracts by UV light 
prior to separation by ion-pair HPLC with fluorimetric detection. The 
peaks shown in a specimen chromatogram took 40 minutes to elute and 
were very broad. Another HPLC separation of tamoxifen from these two 
metabolites, in extracts from rat liver microsomes, was described, 
though not illustrated, by Foster 1980. This operated in the RP mode 
(C column) and a mobile phase of methanol/water/diethylamine 
18 
90/10/1, the last component presumably to sjress solute ionization. A 
Retention tin. es were 4.7 for 4-hydroxy, 8.0 for N-desmethyl and 9.8 for 
tamoxifen and the peak for 4-hydroxy was poorly resolved. 
Sample preparation for plasma extracts has generally been by ether 
extraction from plasma at a pH of 7 or greater. The extraction 
efficiency of tamoxifen and 4-hydroxytamoxifen as a function of pH was 
described by Mendenhall, 1978; as a fairly lipophilic compound the drug 
is not difficult to extract quantitatively. Difficulties in assaying 
tamoxifen lie, rather, in obtaining good chromatography for a compound 
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that is well retained in the reverse phase mode, and contains a polar 
functional group likely to cause long retention in the adsorption mode. 
Ion-pair HPLC thus warrants investigation. 
1.9. Aims of the present research 
The project is concerned with the increasing need to obtain 
reliable analytical values for organic compounds present in crude 
samples at very low concentrations. It is focussed on the use of HPLC, 
especially in the ion-pair mode, for the analysis of drugs and 
metabolites in biological fluids. The aim of this reseirch was to set 
up HPLC systems (in particular based on the ion-pair mode in the case 
of basic drugs), for selected model compounds. The project included 
investigations of how experimental variables, such as choice of column, 
pairing-ion concentration, and temperature could be used for the 
optimisation of conditions and to throw some light on the underlying 
mech4nism, qf separation. Once suitable HPLC conditions were 
forthcoming for the model compounds, satisfactory work-up procedures 
along with specific detection systems were developed, enabling the 
methodology to be applied to plasma spikes and then 'real' plasma 
samples. 
A further aim was to investigate the applicability of using IPC in 
the normal phase mode, with a strongly UV-absorbing or fluorescent 
pairing-ion, to increase the detector signal for molecules possessing 
low native response. Additionally, the feasibility of using an 
optically active pairing ion to separate enantiomers of drug molecules 
possessing a chiral centre was investigated. 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 General reagents and model compounds 
a) Model compounds. 
Propranolol, its 4-hydroxy metabolite and related compounds, 
tamoxifen, its 4-hydroxy and N-desmethyl metabolites and analogues, 
practolol, atenolol and alprenolol were obtained, mostly as salts 
rather than free bases, from ICI Pharmaceutical Division, Alderley 
Edge. The d- and I-isomers of propranolol, atenolol and ICI 129830/1 
were obtained from the same source. 
I 
Chlorpromazine hydrochloride was obtained from May and Baker Ltd., 
Dagenham, its sulphoxide and 7-hydroxy metabolites from the US National 
Institute of Health, Bethesda, and the monodesmethyl and didesmethyl 
metabolites were gifts from Dr. R. Whelpton (London Hospital Medical 
School). Adrenaline nor-adrenaline, S-carboxyethylcysteine and S- 
carboxymethylcysteine were obtained from Sigma (London) Chemical 
Company Ltd., Poole, Dorset. Ephedrine, and N, N-dimethylephedrine were 
obtained from Fluka Chemische, Fabrik, Buch, Switzerland. Of the 
compounds used in HPLC column test mixtures, acetone and toluene were 
obtained from BDH Chemicals Ltd., and phenol o-cresol, 1-naphthol and 
1,3-dinitrobenzene from May and Baker Ltd., Dagenham, Essex; all were 
of A. R. quality. 
b) Buffers and other reagents used to control pH. 
Diammonium hydrogen phosphate, sodium acetate trihydrate, sodium 
dihydrogen phosphate, disodium hydrogen phosphate, ammonium carbonate, 
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trifluoroacetic acid, acetic acid and phosphoric acid were obtained 
from BDH Chemicals. Hydrochloric acid solution 36% and ammonia 
solution 0.90 S. G. were obtained from May and Baker Ltd., and were 
diluted with distilled water to the appropriate concentration before 
use. Sodium hydroxide solutions were prepared from pellets obtained 
from Fisons Scientific Apparatus Ltd., Loughborough. All reagents were 
of A. R. quality or equivalent. 
C) Solvents used for extraction. 
Dichloromethane, 1,2-dichloroethane, ethyl acetate, cyclohexane, 
iso-amyl alcohol, n-octanol, iso-propyl ether, n-hexane and n-heptane 
were all obtained from BDH Chemicals Ltd. The iso-propyl ether 
contained 0.01% hydroquinone to prevent peroxide formation. The iso- 
amylalcohol was known to be a mixture of isomers. Chloroform 
(containing 1-2% ethanol as a preservative) and diethyl ether were 
obtained from May and Baker Ltd. The diethyl ether was passed through 
alumina (Brockman Grade 1, from BDH) to remove any peroxides before 
use. All solvents were A. R. or equivalent quality. 
d) Ion-pairing reagents. 
Sodium heptane sulphonate was obtained from Eastman-Kodak Ltd., 
Rochester, N. Y., sodium perchlorate and sodium naphthalene-2-sulphonate 
from Hopkins and Williams Ltd., Romford, Essex. Sodium d6decyl 
sulphate, methane sulphonic acid, cetrimide, tetrabutylammonium iodide, 
sodium 2-N-morpholinoethane sulphonate, sodium 1,2-naphthoquinone-4- 
sulphonate, and sodium 1,4-naphthoquinone-2-sulphonate were all 
purchased from BDH. Tetrabutylammonium hydrogen sulphate and 
tetrapentylammonium bromide were from Fluka Chemische, tetrahexyl- 
0 
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ammonium iodide from Pfaltz and Bauer Chemicals, obtained through Phase 
Separations Ltd., Queensferry, Flintshire. Aldrich Chemical Company, 
Gillingham, Dorset provided d- and 1-3-bromocamphor-8-sul phonic acids 
as their ammonium salts, d-camphor-10-sulphonate as the ammonium salt, 
1-camphor-10-sul phonate as the monohydrate, benzene tetraethyl ammonium 
chloride and d- and 1-pinanemethylamine hydrochloride. The DMAS came 
as gifts from two sources, Sandoz Ltd., Basel and ICI Pharmaceutical 
Division. 
2.2 Solvents used as HPLC mobile phases 
Methanol, AR was obtained from James Burrough Ltd., London, but 
for most low-wavelength UV and all fluorimetry, HPLC-grade methanol was 
used; this, along with HPLC-grade acetonitrile, was obtained from 
Rathburn Chemicals Ltd., Walherburn, Peebleshire. Dichloromethane, 
1,2-dichloroethane, propan-2-ol, pentan-1-ol and n-heptane were 
obtained from BDH Chemicals Ltd. Chloroform and acetone came from May 
and Baker Ltd., propan-1-ol and butan-1-ol from Hopkin and Williams. 
The last two solvents were of Laboratory Reagent quality and the others 
of A. R. quality unless otherwise indicated. Glass-distilled water was 
prepared 'in-house' using a Jencons 4 plus auto still, Jencons Ltd., 
Leighton Buzzard, Bedfordshire. When dried solvents were required, 
this was achieved by passage through alumina. 
When the mobile phase consisted of mixtures of solvents, as is 
usual, it was degassed before use. Initially this was done under 
vacuum, but for the bulk of the project the eluent was degassed by 
ultrasonication for about 5-10 minutes. This procedure proved very 
effective since very few problems caused by gas bubbles in the detector 
cell were encountered throughout the research. Ultrasonication was 
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preferred to reflux under vacuum, since there was a risk" with the 
latter procedure of altering the composition of the mobile phase if 
very volatile components were present. ' 
2.3 HPLC columns, packing procedures and assessment 
The following RP bonded column materials have been packed and 
used; Hypersil ODS 3 and 5 um, Spherisorb ODS 5 um and Hypersil SAS 5 
pm, all from HPLC Technology Ltd., Macclesfield, C-18, C-8, C-5 and 
phenyl modified silica, 5 pm, all from HSCP Ltd., Bourne End, 
Buckinghamshire. Spherisorb silica, 5 Um from HPLC technology Ltd., 
was also used, along with two polar bonded silicas, viz Lichrosorb diol 
5 um supplied by BDH and Zorbax-CN from Du Pont Ltd., Hitchin, 
Hertfordshire. A 25 cm by 5 mm i. d. Partisil-10 cyano bonded pre- 
packed column was a gift from Whatman Ltd., Maidstone, Kent. All other 
columns used were packed 'in-house'. The empty column tubing, 10,15, 
20 and 25 cm in length by 5 mm i. d., zero-volume end fittings and 
retaining meshes were obtained either from HPLC Technology Ltd., or 
from HETP Ltd., Macclesfield. 
I The column-packing equipment consisted of a solvent reservoir, a 
Haskel MCP-71 air-driven hydraulic pump, an air filter/pressure 
regulator, an on-off valve and a stainless steel slurry bomb. The 
apparatus was purchased from HPLC Technology Ltd. The packing 
procedure involved slurrying the packing material in a suitable solvent 
and dispersing by ultrasonication, pouring the slurry into the packing 
bomb, attaching the column so as to pack upside down [Bristow, 19771 
and then opening the on-off valve so that solvent was pumped through at 
the pre-set pressure of 5000 P. s. i. After the passage of about 250 mls 
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of solvent the column was inverted, the pump turned off, and after the 
pressure had subsided the column was carefully nemoved. The level of 
packing at the column inlet was smoothed flat and the end fitting put 
back in place. Alternatively, if extracts from biological samples were 
to be assayed, the top 2-3 mm of column packing was replaced with glass 
beads (100-120 mesh) to obviate the need for a pre-column. Whichever 
arrangement was used at the top of the columns they generally needed 
'topping-up' from time to time, as revealed by a gap at the top when 
inspected. 
All newly packed columns were tested under standard conditions. 
The test mixture for RP columns contained acetone, phenol, o-cresol and 
1-naphthol with the detector wavelength set at 260 nm. For C 
18 
columns this mixture was eluted by 60% methanol in water, for shorter 
chain lengths the methanol content was dropped to 30-40%- Silica and 
polar-bonded silica columns were tested by injecting toluene and 1,3- 
dinitrobenzene with 1% acetonitrile in n-heptane as the eluent and a 
detector wavelength of 254 nm. Column-testing procedures were 
developed so as to enable deterioration in performance to be monitored, 
and to assess whether a poor separation was obtained, say for a new 
application, due to a poor column or the use of the wrong conditions. 
One further test that was developed applied specifically to RP-bonded 
columns that had been 'capped' - that is, all unreacted silanol groups 
had been treated to provide a completely non-polar surface with no 
adsorptive sites. This test involved using a mobile phase of 1% 
acetonitrile in alumina-dried n-heptane and investigation of the 
retention of 1,3-dinitrobenzene. If this compound has a k' of < 0.5 
then the influence of residual silanolol groups can be ignored. This 
test is useful in assessing whether a bonded phase has been cleaved 
off, but is only applicable to 'capped' packings. 
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When testing columns for efficiency, attention must be paid to the 
mobile phase flow rate since this affects the theoretical plate count 
obtained. In practice the RP columns gave the highest plate counts at 
a flow rate of just under 1 ml/min and the silica columns at 2-3 
mls/min. Column efficiency is sometimes expressed as the reduced plate 
height h, where; 
L 
N dp 
L is the length of the column, N is the number of theoretical plates 
and dp is the diameter of the particles. The lower the value of h, the 
better the column. 
Theoretically, reduced plate heights of %2 are possible, but in 
practice, particularly for bonded phase materials reduced plate heights 
of about 5 are obtained. For a 10 cm column packed with 5 um material 
this represents - 4000 theoretical plates and these were regarded as 
satisfactory plate counts for a newly packed column. Slightly lower 
plate counts were'acceptable later during a columns lifetime. 
Certain steps were taken to try to prolong the life of the columns 
used. The pH working range was kept between 2 and 7.5, and aqueous 
buffers were never left stationary in the column. At the end of the 
day columns were left in methanol, which was also used for prolonged 
storage. To ensure that solvent entering the injector is saturated 
with silica a large particle sil'ica column was placed between the pump 
and the injector. 
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2.4 HPLC equipment 
Throughout this project the HPLC equipment used was assembled from 
component modular units, rather than completely assembled integrated 
units. The basic components are sketched out below (Fig. 1). 
RESERVOIR 1ý FILTERH PUMP ý-j SOLVENT i INJECTOR 
SATURATION 
COLUMN 
WASTE 1-1 DETECTOR! ANALYTICAL 
COLUMN 
RECORDER 
Figure 1. Basic components of a simple HPLC apparatus. 
The pumps used for most of the work were an Altex 110A supplied by 
Anachem Ltd. , Luton, Beds., and a Meteri ng pump from HPLC Technology 
Ltd. Pumps used for short periods were a Pye Unicam LC 20 Separator, 
supplied by Pye Unicam Ltd., Cambridge and a Waters 6000A solvent 
delivery system from Waters Associates Inc., Northwich, Cheshire. All 
punps were used with a mobile phase inlet filter, such as that supplied 
by HPLC Technology Ltd., to protect the pump seals. The pumps 
mentioned above are all constant flow pumps rather than constant 
pressure pumps. 
Sample injection was carried out using sample valves, the Rheodyne 
7120 from Rheodyne Incorporated, Berkeley, Califoria and the Valco 
sample injection valve from Anachem Ltd. The former was used for most 
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of the research. Both have external loops which are filled by syringe 
while the pressurised flow to the column has been diverted. The 
advantages of using injection valves are that the loops are filled at 
atmospheric pressure, yet the interruption to flow through the column 
is kept to a minimum. 
The detector used for the majority of applications was a variable 
wavelength UV monitor. The Pye LCUV from Pye Unicam and the Cecil CE 
212 from Cecil instruments, Cambridge were the most frequently used, 
but the Spectromonitor III from Laboratory Data Control, Stone, 
Staffs., was also used. 
The Schoeffel Fluorescence detector Model FS 970 from Kratos Ltd., 
Manchester was the fluorimeter used most of the time; but the Kontron 
Spectrofluorimeter SFM 23, from Kontron Intertechnique Ltd., St. 
Albans, Herts., was also used. Where thermostatting of the column and 
injector was required, either immersion in a laboratory water-bath or a 
DuPont 830 LC oven, DuPont Instruments, Hitchin, Herts., was adequate. 
The recorders that were used were a CR652 from J. J. Lloyd Instruments 
Southampton, a Linseis flat bed recorder (Linseis GMBH Group, Essex) 
and a Phillips PM8252 (Phillips Electronic Instruments Dept., 
Cambridge). 
2.5 General laboratory apparatus and techniques 
Scans of UV absorption versus wavelength were made using an SP1800 
or SP8-100 spectrophotometer with 1 cm path length cells. Fluorescence 
scans were made using a Perkin Elmer MPF3 fluorimeter or an Aminco 
Bowman scanning fluorimeter. Shaking for solvent extraction was done 
on either a home-made horizontal shaker, or an inverting 
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shaker (Luckham Ltd., Burgess Hill, Sussex) and was performed at room 
temperature. Occasionally a whirlimixer was used (Fisons Scientific 
Apparatus, Loughborough). The choice of system for a particular 
application is indicated at the appropriate point in the text. 
Centrifugation was performed at room temperature in an MSE bench-top 
centrifuge, typically at 2000 r. p. m. When organic solvent extracts 
from biological samples were reduced to dryness, this was achieved 
using apparatus built 'in-house' [Reid, 1981a]. Tubes containing the 
extracts were warmed in an air bath, and exposed to a stream of oxygen- 
free nitrogen. Tubes were observed individually and removed as soon as 
they were dry. 
plasma, whether used for spiking or from 'real' samples, was 
stored at -20*C until just prior to analysis. Where special 
precautions were taken in handling samples, or in the washing of 
glassware, these are indicated in the text in connection with the 
particular compound being assayed. 
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CHAPTER 3 RESULTS AND DISCUSSION 
3.1 Propranolol and analogues 
a) Factors controlling retention and choice of HPLC conditions. 
The UV absorption spectrum of propranolol is shown in Fig. 2. 
This shows a maximum at 215nm and another of about 1/8th the intensity, 
at 295nm. The longer of the two wavelengths was used to monitor the 
HPLC effluent for most of the development work since difficulties 
caused by impurities in solvents can occur at the lower wavelength. 
When dealing with plasma extracts the extra sensitivity obtained by 
using the 215nm maximum is potentially useful, but in practice many 
endogenous co-extractable compounds are likely to interfere at this 
wavelength. 
Two columns were used, 10 cm Hypersil ODS and 25 cm Spherisorb 
ODS, (both are 5um spherical material). 
Using the Spherisorb ODS column, the effect of solvent composition 
on retention and peak shape of propranolol was measured at two 
different PH's. Firstly, methanol/0.1% w/v aqueous ammonium carbonate 
combinations were tried at a pH of about 7.5 in an attempt to suppress 
the ionization of propranolol. This is the highest pH that can be used 
without risking damage to the column. Secondly, methanol/0.1% v/v 
aqueous trifluoroacetic acid (TFA) was used to provide a low pH (%3), 
suitable for ion-pairing. 
Figure 3 shows the results of these experiments. The increase in 
retention of propranolol at very high methanol concentrations for the 
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0. 
0. 
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Figure 2 UV absorption spectrum of propranolol 5ug/ml in 70% methanol 
containing 0-1% TFA 
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mobile phase containing TFA was probably due to the effect of residual 
silanol groups. Spherisorb ODS is not treated for these, and indeed 
when the test for their presence (described in Chapter 2.3) was 
applied, the test compound (1,3-dinitrobenzene) did not elute at all. 
Hypersil ODS, which is reacted to block residual silanol groups was 
also tested and 1,3-dinitrobenzene gave k' = 0.24, showing the virtual 
absence of accessible silanol groups. It was therefore decided to use 
Hypersil ODS for ion-pairing studies with propranolol (on the grounds 
that the hydrophobic surface was expected to be more uniform than for 
Spherisorb ODS). 
The effect of solvent composition on propranolol retention is 
shown in Figure 4, at a pH of 3. There is no increase in retention at 
very high methanol concentrations (c. f. Fig. 3). The effect of TFA 
concentration on propranolol retention is shown in Figure 5, at a 
methanol concentration of 75%. From the data in Figures 4 and 5a 
solvent composition of 0.1% v/v TFA in 70% v/v methanol was selected as 
a solvent suitable for ion-pairing studies with propranolol on Hypersil 
ODS; a 10 cm x5 mm column was used for the studies described below. 
Sodium heptane sulphonate (HS) was chosen as a suitable pairing 
ion since it is easily available, is fairly soluble in solvents likely 
to be used as eluent, is the salt of a strong acid and will therefore 
remain ionized at low pH, and does not absorb in the UV region. 
However, the addition of HS to the eluent at 0.2,1,109 100 and 200 mM 
did not alter significantly the retention of propranolol, although it 
did sharpen up the peaks (from 130 theoretical plates with no pairing- 
ion to about 900 at the highest concentration). 
Extraction studies were then undertaken to investigate whether or 
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Figure 4 The effect of solvent composition on propranolol 
IC 
retention, column Hypersil ODS Mcm,, 5mm 
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Figure 5 The effect of TFA concentration in mobile phase on propranolol 
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-60- 
not HS could increase the partition of propranolol into organic 
solvents indicating that ion-pairing was taking place. The aqueous 
phase consisted of 50 ug/ml propranolol plus 0.1% TFA in water, and for 
each organic solvent the effect of adding 100 mM HS to the aqueous 
phase was studied. For each extraction equal volumes of aqueous and 
organic solvent were whirlimixed for 1 minute at room temperature. The 
extraction of propranolol into the organic phase was determined by 
measuring the UV absorption at 295nm of both the organic and aqueous 
layers. The results are expressed as the log of the extraction 
constant (defined in Chaper 1.4c as equation (4)) and are shown in 
Table 1. 
Tabl e 1. Log (extraction constant) for propranolol in the absence and 
presence of heptane sulphonate 
organic solvent No heptane sulphonate With O. lM heptane sulphonate 
Heptane None extracted None extracted 
Dichloromethane 0.15 3.6 
Ethyl acetate 0.93 2.4 
Amyl alcohol 1.6 2.04 
The extraction experiments show that an ion-pair is being formed 
between propranolol and HS under the conditions used, despite the lack 
of effect on the HPLC retention of propranolol. Consequently a longer 
chain pairing ion (sodium dodecyl sulphate, SDS) was added to the HPLC 
eluant used previously (0.1% TFA in 70% methanol). The effect of SDS 
concentration in the mobile phase on propranolol retention and number 
of theoretical plates is shown in Figure 6. Several structural 
analogues of propranolol were available and these were chromatographed 
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Fiqure 6 Variation of k"of propranolol with SDS concentration in eluent 
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along side. The structures are shown in Table 2. The compounds are 
all closely related to propranolol (shown below). 
CH. 5 H. NH. CH(CH 3ý2 
R 
R4 
o 
R 
The plot of k' versus SDS concentration in the mobile phase is the same 
for propranolol and all the analogues. 
The temperature of the column and mobile phase present within the 
column also affects chromatographic behaviour. The effect of 
temperature on propranolol retention was investigated using 10 mM SDS 
pi us 0.1% TFA in 70% methanol , again, on a 10 cm Hypersi 1 ODS column 
(Figure 7a). These results are discussed in section 3.1d, but it can 
be seen that raising the column temperature from 250C to 400C reduced 
k' by nearly half. Figure 7b shows that a plot of log k' against 
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Figure 7 The effect of temperature on propranolol retention 
A (a) k, versus temperature 
retention M 
10 y Column Hpersil ODS 10cm. 5mm 
Mobile Aase 0.1% TFA plus-lOmM SDS 
(2200) in 70% methanol 
Flow rate 1.0 ml/min 
Detector UV at 295nm 
Numbers in () are theoretical 
plates 
6 
2300) 
2100) 
2100) 
2-4 (2000) 
30 40 so 60 70 
0 temperature C 
(b)log k versus 
reciprocal of 
temperature 
log k 
0. 
0. 
0. 
2.9 3.1 3.3 
lOx, IIT (K) 
-65- 
reciprocal temperature is linear, which is in agreement with 
conventional theory [Hearn, 1980]. 
b) Development of an assay method and application to biological 
samples. 
Propranolol, its 4-hydroxy metabolite (ICI 151933) and three other 
analogues (ICI 48112,52487 and 51932), as possible internal standards, 
were chromatographed with a view to setting up a plasma assay method. 
A typical chromatogram along with HPLC conditions is shown in Figure 8. 
From the results it was decided that ICI 51932 and ICI 52487 had 
retention times most likely to prove useful for an internal standard, 
with ICI 48112 having a rather longer retention time. In order to 
measure plasma levels of propranolol likely to be encountered in Ireal 
samples' it was decided that extra specificity and sensitivity might be 
required and therefore a fluorimetric detector was employed. 
Figure 9 shows (a) the emission spectrum for propranolol when 
excited at 290nm, (b) the excitation spectrum of propranolol when the 
emission is at 347nm. 
The results show that the best sensitivity and specificity might 
be expected if the HPLC effluent is excited at 290nm and the light 
emitted at 347nm is monitored. However, a second excitation peak of 
lower intensity is shown at 222nm; the fact that it is of lower 
intensity maybe due to the fact that the scanning fluorimeter is fitted 
with a Xenon lamp, which has a relatively low output at 222nm. Since 
two HPLC fluorimetric monitors were available, the Schoeffel fitted 
with a deuterium lamp, and the Kontron fitted with a xenon lamp, it was 
decided to compare them. The deuteriLin lamp (Schoeffel) was used to 
3 
, 
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Figure 8 Propranolol and some analogues 
chromatographed on Hypersil ODS 
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Figure 9 Fluorescence scan of propranolol (lug/ml in 0.1% TFA) 
Aminco-Bowman Fluorimeter, lcm pathlength 
(a) emission spectrum witý, excitation at 290nm 
(b) excitation spectrum with emission at 347nm 
(b) 288nm (a) 347nn 
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excite at 222nm, with a 320nm filter to absorb any emitted light below 
320nm, whereas the Kontron with the xenon lamp, has monochromators both 
for excitation (set at 288nm) and emission (set at 347nm). Using the 
222nm excitation proved much more sensitive than using the 288nm 
excitation. For example, using the xenon lamp, I ng on column at high 
sensitivity, gave a signal to noise ratio of approximately 3, whereas 
on the same day using the deuterium lamp 50 pg on column gave a signal 
to noise ratio of about 5. Consequently, for all future experiments 
where fluorescence detection was necessary, the Schoeffel fluorimeter 
was used, with the excitation wavelength set at 222nm and a 320nm 'cut- 
off' filter. 
Extraction studies were then undertaken using 1 ml of plasma 
spiked with; 0,5,10,20 and 50 ng/ml propranolol, its 4-hydroxy- 
metabolite and ICI 51932 and 52487 as possible internal standards. 
Since propranolol is basic and fairly lipophilic the pH of the plasma 
was raised by the addition of 0.5 mls of IM sodium hydroxide and the 
samples shaken for 20 minutes with 5 mls of 1.5% amyl alcohol in n- 
hexane. The organic layer (4- mls) was evaporated to dryness under 
nitrogen, redisolved in 500 ul of 0.1% v/v TFA in 70% v/v methanol and 
50 jil injected into the HPLC. The resultant chromatograms for the 
blank and 50 ng/ml spike level are shown in Figures 10a and 10b 
respectively. A UV detector operated at 215 nm was also used (in line 
before the fluoromonitor), but the trace showed so many co-extracted 
peaks from plasma that no measurements could be made. Using the 
fluorescence trace ICI 52487 was chosen as a suitable internal 
standard. A plot of peak height versus plasma concentration spiked, 
for both propranolol and ICI 52487 is shown in Figure 11. Two peaks 
appeared on the chromatogram as co-extractable material from plasma, 
one clashing with the ICI 51932 peak, the other a long running peak at 
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Fiqure 10 Chromatogram of plasma extracts spiked with 
propranolol and analogues 
1 
Extraction solvent-l. S% amyl alcohol iq hexane 
Column Hypersil ODS 5pM 10cmx5mm at 40 C 
Eluant 0.1% TFA in 7b% methanol plus lOOmM SDS 
Flow rate 1.4ml/min 
Detector Schoeffel fluorimeter 222 excitation 
320 cut off filter 
(a) Blank plasma extracts 
2 
Ktracts from plasma spiked with 
ropranolol and analogues (50pg/ml) 
eak identification 
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1= ICI 51932 plus 
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3= Propranolol 
4= Endogenous peak 
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Retention time (min) 
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Peak height (mm) 
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Figure 11 Standard curves of propranolol and ICI 52487 spiked into 
plasma 
HPLC conditions as in Fig. 10 
Extraction solvent 1.5% amyl alcohol in hexane 
Plasma concerKration(ng/ml) 
about 14 minutes. The 4-hydroxy propranolol did not co-extract. 
A standard curve of propranolol and 4-hydroxy propranolol was 
spiked into 1 ml plasma and extracted into 5 mls of 1.5% amyl alcohol 
in n-hexane after the addition of aqueous ammonia, subsequent steps 
were as for the previous experiment. The levels spiked were 0,0.5,1, 
2,5,7.5,10,15 and 20 ng/ml and 5 ng of ICI 52487 was added to each 
tube (except the blank), as internal standard. 
Examples of the chromatograms obtained are illustrated by Figure 
12a (blank) and Figure 12b (10 ng/ml spike). The results are plotted 
as peak height ratio versus plasma concentration in Figure 13a. The 
same samples (at this stage in 0.1% v/v TFA in 70% Methanol) were 
dissolved in 1 ml of 0.2 M HCI, shaken with 1.5% amyl alcohol in 
hexane, and the organic layer discarded. They were then alkalinised by 
the addition of 2 mls 2M ammonia solution and re-extracted into 1.5% 
amyl alcohol in hexane, dried down and injected as before. This was to 
simulate what would have happened had the samples been put through a 
back extraction. The resultant standard curve is shown in Figure 13b, 
and examples of the chromatogram obtained, shown in Figure 14(a) for 
plasma blank and 14(b) for plasma spiked at the 10 ng/ml level. The 
back-extraction was no cleaner than the single extraction and therefore 
offered no major advantages. The 4-hydroxy metabolite did not co- 
extract and was therefore not investigated further. 
Another standard curve was obtained by spiking propranolol into 
plasma at; 0,0.5,1,2,5,10,15 and 20 ng/ml with 5 ng of ICI 52487 
as internal standard. This was worked up as in the previous experiment 
except that 0.5 ml of M sodium hydroxide solution was used to raise the 
pH, 1.5% amyl alcohol in n-heptane was used as the extracting solvent 
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Figure 12 Chromatogram of extracts from plasma spiked 
with propranolol and ICI 52487 (internal standard) 
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Figure 14 Chromatogram of extracts from plasma spiked with propranolol 
and internal standard (ICI 52487) 
Extraction into 1.5% amyl alcohol in hexane, back extraction 
into HCL and re-extraction into amyl alcohol in hexahe 
HPLC conditions as on Fig. 10 
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and only a single extraction was performed. The resultant 
chromatograms were very similar to those in Figure 14a and 14b and are 
therefore not illustrated. Again an excellent standard curve was 
obtained ,r=0.995 (Table 3). 
Tabl e3 Peak height ratio for propranolol extracted from plasma by 
1.5% amyl alcohol in heptane. 
ng spike Propranolol pea Internal standard 
height (m m. ) peak height (m, m 
0 0 0 
0.5 7 70 
1.0 18 108 
2.0 41 146 
5.0 59 94 
10.0 183 162 
15.0 78 44 
20.0 318 157 
Peak heiqht ratio 
0 
0.10 
0.16 
0.28 
0.63 
1.13 
1.78 
2.03 
S 
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There is considerable variation in recovery, as reflected by the 
internal standard peak height, probably due to the emulsions that 
formed in some tubes. Two further variations in sample preparation 
were tried, firstly, using cyclohexane as extracting solvent and 
secondly, using pH8 buffer to control the pH rather than aqueous 
ammonia or sodium hydroxide. Neither of the variations improved the 
results, although the use of 5 ml of 0.2M diammonium hydrogen phosphate 
to control the pH did not adversely affect the proposed method. 
As a final validation of the assay, plasma samples from a patient 
who had twice received an oral dose of a long-acting formulation of 
propranolol [Inderal L. A. ] were analysed (these had already been 
analysed by an existing GLC method. The sample preparation procedure 
involved shaking 1 ml plasma with 5 mls 1.5% amyl alcohol in heptane 
after the addition of 0.5ml of ammonium phosphate pH9 buffer. The 
organic extracts were evaporated to dryness and redissolved in 250 Ul 
of 0.1% v/v TFA in 70% v/v methanol, with 50 Ul injected onto the HPLC 
using the conditions described in Figure 10a. 
The standard curve obtained is shown in Figure 15. The range it 
covered was 0-60 ng/ml, so 10 ng of internal standard was spiked. 
Examples of the chromatograms are shown in Figures 16a, b, c and d for a 
&n& 1-0 
blank, spiked pl asma (10 A ng/ml and a sample from a patient, 
respectively. A comparison between the results obtained by this HPLC 
method and the existing GLC method is shown in Table 4, and the HPLC 
results from Table 4 plotted in Figure 17. 
I 
-77- 
Figure 15 Standard curve of propranolol spiked 
into control plasma 
Peak height ratio 
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Figure 16 contd. HPIC conditions, extraction and peak 
identification as on Fig. 16a and 16b 
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Figure 17 Plot of log (propranolol plasma concentration) 
against time after oral dose 
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10 
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Table 4 The comparison of Propranolol plasma concentrations determined 
by two methods 
GLC result (ng/ml) HPLC result (ng/ml) 
None detected 1 
7 2 
9 11 
22 32 
23 23 
37 38 
32 36 
32 31 
31 27 
25 26 
53 23 
61 49 
- 66 
51 60 
53 56 
54 55 
23 42 
23 25 
A paired 't' test showed that there was no significant difference 
between the results from the two methods (P = 0.99). The 
reproducibility of the method was checked by spiking the 1 and 10 ng/ml 
propranolol standards four times. The 1 ng/ml level gave peak height 
ratios of 0.092,0.082,0.090 and 0.076, mean 0.085, C. V. = ±8.7%. The 
10 nglml level gave peak height ratios of 0.686,0.684 and 0.699 to 
give a mean of 0.690 and a C. V. of ±1%. The recovery of propranolol, 
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using the sample preparation procedure described, was about 50%. 
However, the recovery when using aqueous ammonia to raise the pH was 
about 75%, and for this reason aqueous ammonia would be recommended for 
future use. 
C) Investigation of the underlying mechanism of separation. 
The chromatography of ionized solutes on RP columns, using an 
oppositely charged 'pairing-ion' present in an aqueous eluant, has 
stimulated some controversy about the underlying mechanism of 
separation. Doubt has arisen as to whether or not the equilibrium 
described in equation (3) represents IPC over the wide range of 
conditions possible. It has often been suggested that adsorption of 
pairing-ion from the eluent takes place when chemically bonded reverse- 
phase, columns are used (these points are discussed more fully in 
section 3.1d). 
The amount of SDS adsorbed onto Hypersil ODS from the mobile phase 
containing different concentrations of SDS (as in Figure 6) has been 
experimentally determined. This was achieved by equilibrating the 
column with different concentrations of SDS in the eluent and 
determining propranolol retention. The column was then removed from 
the solvent stream and the lines were flushed with methanol. The 
column was then replaced and adsorbed SDS was washed from the column 
with 100 mls methanol and collected. The amount of SDS contained in 
the methanol washings was determined spectrophotometrically. A 
suitable aliquot of the methanol was evaporated to dryness and then 
redissolved in 0.01 M phosphate buffer (pH 7.0). Benzene 
tetramethylammonium chloride (BTEAC) was added as a pairing-ion and the 
SDS was determi ned spectrophotometrically as an ion-pair after 
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extraction into 20% n-pentanol in ether. A wavelength of 263 nm was 
used as this is the maximum for BTEAC. A standard curve of SDS 
concentration versus absorbance at 263 nm is shown in Figure 18. The 
amount of SDS present in the mobile phase contained in the column (ie 
equal to the column dead volume) was subtracted from the amount found 
in the methanol washings. The amount of SDS adsorbed onto a 10 cm 
Hypersil ODS column is plotted against the eluent SDS concentration in 
Figure 19a, and k' for propranolol (from Figure 6) versus the amount of 
adsorbed SDS, is shown in Figure 19b. 
d) Discussion of results. 
The retention of propranolol on Spherisorb ODS, illustrated in 
Figures 3a, at low pH (about 3) and 3b, at high pH (about 7.5), shows 
that the drug is better retained at the higher pH. This is expected, 
since for a basic drug raising the pH increases the concentration of 
the undissociated form of the drug, thereby increasing its tendency to 
partition into the organic stationary phase. At very high methanol 
concentrations (Figure 3b), an increase in propranolol retention 
occurs, probably due to the effect of residual silanol groups, since 
the 'capped' Hypersil ODS column does not exhibit this behaviour 
(Figure 4). Figure 3a shows a linear dependence of log W on solvent 
composition; this is also shown in Figure 3b except at very high 
methanol concentrations. Retention decreases as the concentration of 
methanol is increased. 
Methanol-water mixtures were chosen for this attempt to set up an 
ion-pair chromatographic system for propranolol, since many of the 
commonly used ion-pair reagents are more soluble In methanol than other 
organic modifiers. Control of pH is an important parameter when 
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Figure 18 Standard curve of SDS using ion-nair extraction 
with benzene tetraethyl ammonium chloride 
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settingý up an ion-pair separation as it dictates the concentration of 
the ionic form of the solute. In this experiment TFA was used to keep, 
the pH low, *though an aqueous buffer could also have been used; Figure 
5 shows that below about 0.05% v/v TFA retention begins to increase 
drastically (0.1% v/v TFA was subsequently used, this is about 10 mM). 
Hypersil ODS (10 cm by 5 mm) was the column chosen for future 
experiments since it is 'capped', so that the effect of residual 
silanol groups-is minimised. A mobile phase composition of 0.1% v/v 
TFAAn 70% v/v methanol was selected as suitable for the addition of a 
pairing-ion because, under these conditions, propranolol is not well 
retained and the pH should ensure maximal ionization of the drug. 
,. The addition of HS to the mobile phase did not alter the retention 
of propranolol despite its ability to extract the drug into organic 
solvents of moderate polarity. -- However, the addition of a pairing-ion 
with a longer alkyl-chain, (SDS) showed increased solute retention even 
at fairly low pairing-ion concentrations. Figure 6 shows the 
dependence of k' for propranolol on SDS concentration in the eluent. 
Up to an SDS concentration of 40 M retention increased with increasing 
1> 
pairing-ion concentration but above that concentration the retention 
decreased. Several analogues of propranolol were co-chromatographed 
and all showed exactly the-same shaped plot (results shown in Table 2). 
This, decrease in retention at high SDS concentrations has been 
attributed to micelle formation [Knox, 1976 and Gloor, 19771, which 
could increase the solubility of the ion-pair in the mobile phase. 
From the viewpoint of multisample analysis, the use of 100 mM SDS is 
recommended for this. system since the highest plate count (Figure 6) 
was obtained at this ý pairing-i on concentration and the retention time 
was, not too long. Increasing the column temperature further decreased 
retention time (with no loss of efficiency) thereby decreasing the 
- 
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running time for each sampl e, without adversely affecting the 
separation. Figure 7b shows that a plot of log k' versus the 
reciprocal of the absolute temperature is linear, which is in agreement 
with data published by other authors for bonded phase separations 
[Melander 1978, Snyder 19791. 
Although most of the pilot work was undertaken using UV detection, 
the -aim, when applying these chromatographic conditions to plasma 
samples, was to take the limit of detection down to 1-2 ng/ml so 
fluorimetric detection was investigated. The Schoeffel fluorimeter 
(fitted with a deuterium lamp), proved most suitable, with an 
excitation at 222 nm and a 320 nm emission cut-off filter providing 
excellent sensitivity. 
Propranolol analogues were chromatographed in the search for an 
internal standard that would closely mimic the properties of the parent 
drug. The compound ICI 52487 was found to chromatograph very closely 
to propranolol (Figue 8) and furthermore, extraction studies (such as 
that shown in Figure 11) showed that both ICI 52487 and propranolol 
gave a linear recovery from plasma over the 0-50 ng/ml range 
investigated. This compound (ICI 52487) differs from propranolol only 
by the addition of a methoxy group, so its close resemblance to 
propranolol in extraction and chromatographic properties is not 
unexpected. The plasma was clear in the region where propranolol and 
ICI 52487 chromatographed but a peak from plasma interfered with ICI 
51932 so this was not considered further as an internal standard. A 
single solvent extraction using a non-polar solvent was found to be 
satisfactory for clean-up. Cyclohexane, n-hexane and n-heptane all 
containing a small proportion of amyl alcohol were tried. There was 
little difference between them but n-heptane is recommended since the 
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other two gave emulsions (easily removed by centrifugation) in some 
tubes. Back extraction into acid was tried but this did not give 
cleaner chromatograms (Figures 12 and 14), and since recoveries were 
lower, this was not pursued further. There was little difference in 
the quality of definition of chromatograms when using either pH8 
buffer, aqueous ammonia, or sodium hydroxide solution to raise the pH, 
but aqueous ammonia gave the highest recovery (% 75%) so this was the 
reagent of choice. 
All the standard curves prepared have shown excellent correlation 
(r = . 987 is the lowest) between peak height ratio 
(propranolol/52487) 
and concentration of propranolol spiked into plasma. The major 
metabolite, 4-hydroxy-propranolol did not interfere since it separated 
on the HPLC, and did not co-extract. In order to show the 
applicability of the method to 'real sample', 18 plasma samples from a 
patient receiving propranolol were analysed. These samples had 
previously been analysed by a GLC method. A comparison of results from 
the two methods is shown in Table 4. A paired 't' test showed that 
there was no significant difference between the two sets of results. 
As mentioned earlier, the recovery of propranolol from plasma, 
compaired with a non-processed standard, is good, about 75% when using 
aqueous ammonia to adjust the pH. The reproducibility of the method, 
measured by replicating extracted standards at two different 
concentrations was excellent, ± 8.7% at the 1 ng/ml level and ± 1% at 
the 10 ng/ml level. This emphasises the value of using an internal 
standard closely related chemically to the solute to be determined, 
spiked at the very beginning of the procedure, as was the case here. 
The limit of detection for this assay is approximately 1 ng/ml. An 
example of a chromatograA obtained from a standard spiked into plasma 
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at this level is shown in Figure 16c. The limit of detection was 
determined using a confidence-limit approach based on statistical 
analysis of a calibration plot proposed by McAinsh 1981. If the 
'double the background noise' approach had been used the figure quoted 
would be even less, say -, 0.5 ng/ml. 
The results quoted in Table 4 form two pharmacokinetic profiles, 
shown in Figure 17. Improvements that could be made to this assay 
would include removing the long running peak co-extracted from plasma 
(Figures 10,12,14,16), thereby shortening the analysis time. A further 
improvement would be to extend the method to allow measurement of the 
4-hydroxy metabolite of propranolol. This would probably require the 
use of a more polar extracting solvent, consequently more clean-up 
would also be necessary. 
The use of long chain pairing-ions, such as SDS, in the eluant to 
enhance the retention and improve the peak shape of ionized solutes has 
been used previously by other workers [eg. Knox 1976a and Riley 1979]. 
These authors believed that the pairing-ion was adsorbed onto their 
reverse phase column, possibly to form an "in situ" ion-exchange 
column. Figure 19a confirms that in the system described here for 
propranolol, SDS is certainly adsorbed by the Hypersil ODS. The linear 
relationship between adsorbed SDS and its eluent concentration 
(illustrated in Figure 19a, up to 80 mM, was also described by 
Tomlinson 1979, when using alkyldibenzyl dimethyl ammonium chlorides up 
to 1 mM in the eluent. Further comments on mechanistic models for IPC 
will be made later in Chaper 4. 
r-, -- 
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3.2 Chlorpromazine and metabolites 
a) Development of chromatographic*conditions. 
It was reported [Watson, 1979] that various drug compounds, 
including chlorpromazine and metabolites, were amenable to straight- 
phase separation on silica with dichloromethane or chloroform 
containing an optimized proportion of methanol or propan-2-ol, possibly 
with ammoýia added to suppress solute ionization. Similar HPLC 
conditions for chloropromazine were tried but gave results which were 
discouraging, for even with long equilibrium times retention times 
showed unacceptable variability. Solvent re-cycling the previous night 
did help slightly. Whilst a satisfactory peak was obtained for 
chlorpromazine, eg. with dichloromethane containing 10% propran-2-ol 
and 0.2% aqueous ammonia (sg. 0.88) chloropromazine sulphoxide and 7- 
hydroxychloropromazine were too well retained. 
Satisfactory retention times, viz. 2.7,3.2 and 2.4 min 
respectively for the three compounds, were obtained in a silica system 
-1 
with methanol containing 1% ammonia, run at 2 ml min However, 
interfering peaks were observed with plasma blanks as examined after 
applying the 3-step extraction procedure described for chlorpromazine 
assay, by Curry 1976. 
Reverse-phase HPLC on C-18 silica (Hypersil ODS) was tried, but 
chlorpromazine (which is fairly lipophilic) was too well retained and 
showed broad peaks even with very high concentration of organic 
modifiers in the mobile phase. If bonded-phase separation were to be 
further investigated, the best packing might be CN-silica as recently 
reported to be effective for chorpromazine and metabolites, (Midha 
-91- 
1981, Curry 1981). 
Trial of ion-pair HPLC with a silica column was done in the first 
instance with perchlorate as the pairing-ion. Under conditions 
described for amitriptyline [Mellstrom, 1978] (0.1 M perchloric acid/ 
methanol /d i chl oromethane/di i sopropyl ether, 0.9 : 5.2 : 10 : 30 by vol. ), 
chlorpromazine gave a very broad peak with a retention time of about 6 
min, and even after prolonged equilibrium the system gave baseline 
stability problems. Success came with the trial of the system 
described below (HS as pairing-ion), where the pairing-ion is present 
in the mobile phase but not pre-applied to the silica packing. 
Satisfactory separation of chlorpromazine and four metabolites 
(the 7-hydroxy, monodesmethyl and didesmethyl metabolites and the 
sulphoxide), was achieved under the chromatographic conditions 
described below. A 20 or 25 cm column containing Spherisorb 5 silica 
was used with a mobile phase of 0.1% v/v TFA, in 70% v/v methanol 
containing HS as pairing ion. Detection was by UV at 250 nm (for 
chlorpromazine) and 260 nm (for 7-hydroxy-chlorpromazine). Table 5 
shows the retention times for chlorpromazine and metabolites at two 
different heptane concentrations. 
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Table 5 Peak Positions for Chlorpromazine and Metabolites Separated on 
Silica Columns (25 cm x5 mm i. d.; Spherisorb 5). The Eluent (See 
Text) Contained Heptane Sulphonic Acid as an'lon-Pairing Agent. 
Retention time, min Retention time, min, 
(and no of theor- with 2 mM heptane 
etical plates) with sulphonate. 
10 mM heptane sul- 
Compound pho nate 
Chloropromazine 3.8 (6600) 4.7 
Chlorpromazine sulphoxide 5.8 (4200) 8.4 
7-hydroxychlorpromazine 3.2 (5500) 3.9 
Monodesmethylchlorpromazine 2.9 (4700) 3.5 
Didesmethylchlorpromazine 2.6 (3100) 3.1 
As is evident from Table 5, separation of all five compounds was 
achieved at 10 mM HS and even the longest running metabolite eluted 
within six minutes. However, 7-hydroxychlor-promazine eluted so early 
that when pilot assays on plasma samples were performed, it sometimes 
merged with early running peaks present even in plasma blanks. This 
difficulty was overcome by lowering the heptane sulphonate 
concentration from 10 mM to 2 mM (peak position shown in Table 5) when 
7-hydroxychlorpromazine was assayed. As already mentioned, the 
measurement of 7-hydroxychlorpromazine called for an independent 
extraction at the outset, so the need for a separate HPLC run did not 
constitute too severe a handicap. Two separate assays were therefore 
necessary. 
With the 2 mM concentration, the sulphoxide ran as a late broad 
peak which precluded quantitation, although chlorpromazine itself could 
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be quantitated concomitantly with 7-hydroxychlorpromazine if desired 
(Tabl e 5). The compromise choice of two heptane sulphonate 
concentrations, 2 and 10 mM, was in fact based on a systematic study, 
implications of which are explored in the Discussion below. 
b) Application to plasma samples. 
To obtain clean blanks in the present procedure for chlorpromazine 
and its sulphoxide, it was found unnecessary to follow up heptane 
extraction (at alkaline pH) with back-extraction and re-extraction (as 
in S. H. Curry's 1976 GC procedure). No such short-cut was feasible in 
the case of 7-hydroxychlorpromazine; nor were clean blanks obtained if 
an ether extraction step was applied to plasma that had already been 
extracted with heptane and brought to near-neutral pH (eg. withiM 
phosphate buffer). Another reason for abandoning attempts to have one 
plasma sample double up for the two assays was phase-separation 
difficulty in the second of the serial extractions: an intractable gel 
tended to occur, as a voluminous interface layer. In trying procedural 
variants, results were worse rather than better if diethyl ether were 
wholly or partially replaced by a solvent such as ethyl acetate or 
dichloro-ethane or -methane, or if a propan-2-ol procedure that 
effected deproteinization was applied to the plasma initially [Midha, 
19811. 
For chlorpromazine and its sulphoxide therefore, sample 
preparation consisted only of a single amyl alcohol in heptane 
extractiong from plasma made alkaline by the addition of sodium 
hydroxide. For 7-hydroxychlorpromazine sample preparation consisted of 
ether extraction from plasma made alkaline by the addition of ammonia, 
back extraction into acid and subsequent-re-extraction into ether, 
I 
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With the 7-hydroxychlorpromazine assay there were problems besides 
obtaining a satisfactory load sample for HPLC. Personal communications 
from S. H. Curry and R. Whelpton confirmed that photodecomposition, acid 
lability and adsorption onto glassware had to be guarded against. 
These points have been discussed elsewhere [Stevenson 1981, Midha 1981, 
Desager 19781. 
Figure 20 shows representative chromatograms for spiked and 
-A 
unspiked plasma, processed and chromatographed as described in the 
text. They allow quantitation, with negligible interference from 
endogenous constituents. Representative calibration curves are shown 
in Figure 21, with satisfactory linearity. The computed regression 
lines showed correlation coefficient (r) values of 0.990,0.976 and 
0.982 for chlorpromazine, chl orpromaz i ne sulphoxide and 7- 
hydroxychlorpromazine respectively, and the computed y-intercept was in 
the position of the blanks. The recoveries, corrected for aliquot 
taking were; 80%, 76% and 60% and the coefficients of variation (C. V. ) 
were 9.4% (at 27 ng/ml), 8.2% (at 27 ng/ml) and 16% (at 10 ng/ml) for 
CA 10 ý" 
P $-a M dL -SI Jý e 
chlorpromazine, the sulphoxide and 7-hydroxyA respectively. The C. V. 
values are acceptable though they are better at higher levels, 8.5% 
(180 ng/ml), 7.8% (180 ng/ml) and 9.1% (100 ng/ml) respectively. No 
14 
improvement in precision resulted from the use of C-chl orpromazi ne 
as internal standard. For each of the compounds levels as low as 10 
-1 
ng/ml were measurable. 
C) Investigation of underlying mechanism of separation. 
As mentioned in section 3.2a the choice of two heptane sulphonate 
eluant concentrations was based on a systematic study of its effect on 
retention. Using an eluant composition of 0.1% V/v TFA in 70% 
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Figure 20 Specimen chromatograms of extracts of unspiked 
plasma and plasma spiked with(A) chlorpromazine 
and chlorpromazine sulphoxide (B) 7-hydroxychlorpromazine 
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Figure 21 Standard curves of (A) chl-orpromazine (B) chlorproriazine 
sulphoxide and (C) 7-hydroxychlorpromazine spiked into 
plasmdLthen proýcessed as in the text 
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methanol, the heptane sulphonate concentration was varied and 
chlorpromazine and four metabolites were chromatographed. 
Table 6 The effect of heptane sulphonate eluant concentration on the 
retention of chlorpromazine and metabolites. (Expressed as .k 
(Heptane sulphonate concentration in eluent (mM)) 
Compound 0125 10 20 50 
Chlorpromazine 1.80 1.57 1.48 1.10 0.95 0.62 0.43 
7-hydroxychlorpromazine 1.23 1.05 0.95 0.71 0.57 0.38 0.24 
chlorpromazine sulphoxide 3.95 3.38 3.10 2.52 2.14 1.38 1.00 
monodesmethylchlorpromazine 1.00 0.86 0.81 0.57 0.48 0.31 0.19 
didesmethylchlorpromazine 0.71 0.62 0.57 0.40 0.33 0.19 0.10 
These results are discussed in the next section, as an aid to 
understanding the predominant mechanism of separation. 
d) Discussion of Results. 
The present HPLC system described gave short retention times and 
sharp peaks that readily allowed chlorpromazine, and its 7-hydroxy and 
sulphoxide metabolites to be quantitated. 
Not unexpectedly, silica columns tried in the conventional mode 
with low-polarity eluents showed irreproducibility of retention times. 
The present approach, viz. an ion-pair system with a silica packing 
with no pre-application of a liquid stationary phase, has precedents. 
For examples the addition of cetrimide to a mobile phase consisting of 
75% aqueous propanol increased the retention of sulphonic acids [Knox, 
19761. Similarly, the addition of a quaternary ammonium compound 
increased the retention of anionic species, and the addition of 
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camphor sulphonate increased the retention of cationic species 
[Crommen, 19791. Such effects of a pairing ion on retention time with 
an aqueous eluent are similar to what has been observed with columns of 
reverse-phase (alkyl) type with [Schill, 19761 or without [Knox, 1976] 
pre-application of an organic stationary phase. 
Decreased solute retention, as in the system now adopted, on 
adding increasing amounts of a pairing ion to the eluent has been 
observed elsewhere with a conventional system. An above-mentioned 
study [Mellstrom, 1978] where the retention of amitriptyline and 
metabolites decreased exponentially with increasing concentration of 
pairing ion (perchlorate) in the mobile phase, was followed by Greving 
(1979) with bromide or perchlorate as pairing-ion for basic drugs and 
quaternary ammonium compounds. These authors investigated the nature 
of the chromatographic mechanisms by applying a simple Freundlich-type 
equation to the data obtained when determining the effect of pairing 
ion concentration in the mobile phase on retention of solutes. 
Straight-phase ion-pair adsorption systems obey the equation; 
k' = a[X-]b 
where EX I is the concentration of pairing ion, k' is the phase 
capacity ratio of a solute, and a and b are constants. Thus, if an 
ion-pair adsorption process is the dominant mechanism of separation, 
then a plot of 1n k' versus 1n EX would yield a straight line. 
Application of a double-logarithmic plot to the data now obtained for 
chlorpromazine and its metabolites is shown in Figure 22. The 
correlation coefficients for the various compounds were all 0.97 or 
greater, indicating that the mechanism of separation was predominantly 
adsorption chromatography. 
If ion-pair partition chromatography were the dominant mechanism, 
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Figure 22 Double logarithmic plot of k"for chlorpromazine 
and metabolites against heptane sulphonate concentration 
in eluant 
HPLC conditions as on Fig. 20 (except for heptane 
sulphonate concentration) 
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then the relationship between phase capacity ratio and pairing ion 
concentration would be defined by the equation; 
kl =1- 
vs 
Kex [X-] vm 
[Schill, 19781, where K is the extraction constant for the ion pair 
ex 
and V /V is the phase-volume ratio. Thus, a plot of k' against 
1/[X ] would yield a straight line. However, when such plots were 
-SM 
applied to our data, the correlation coefficients were lower (r <0.89) 
than for the double-logarithmic plot. Thus, it may be concluded that 
any partition processes are less important than adsorption processes in 
the system now described. 
The present procedures were applied to an investigation of 
schizophrenics given chlorpromazine (daily dose about 0.4 mg) with or 
without propranolol [Peet, 19801. The results are summarised in Table 
7. 
Table 7 Plasma chlorpromazine levels in patients given chlorpromazine 
alone or in combination with propranolol. 
Chlorpromazine nq/ml 
Week 1 Week 2 Week 3 
Without propranolol. 27.6 6.4 19.0 ± 4.4 15.3 t 4.9 
With propranolol 51.3 21.2 64.7 ± 19.9 85.2 ± 18.0 
This shows that plasma levels of chlorpromazine are elevated when given 
in combination with propranolol. The assay was satisfactory in respect 
of reproducibility, specificity and ease of execution for the analysis 
I 
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of about fifty patient samples in this laboratory. 
0 3.3 Tamoxifen and metabolites 
a) Development of chromatographic conditions. 
Tamoxifen is a UV absorbing compound with an absorption maximum at 
240 nm. Since both the N-desmethyl and 4-hydroxy metabolites have a 
maximum close to this wavelength, it was chosen as the detector 
wavelength for monitoring HPLC effluent. The columns tried initially 
for chromatography of tamoxifen, and desmethyl tamoxifen, were 25 cm 
Spherisorb 5pM ODS and 10 cm Hypersil 5uM ODS. Using the Spherisorb 
column, no peaks eluted when using pH3 or pH7 . 01M phosphate buffer 
with up to 80% acetonitrile as eluant. On the shorter, Hypersil ODS 
column, tamoxifen had a retention time of 16 mins and desmethyl 
tamoxifen 13.6 min, using 80% acetonitrile 20% pH3 . 01M phosphate 
buffer. The peaks were very broad, and the conclusion was that these 
compounds were too lipophilic for good chromatography on a reverse- 
phase column of this chain length. It was decided that a less 
hydrophobic stationary phase might be more successful. At this stage 
of the project 4-hydroxytamoxifen was not yet available, so retention 
data were not obtained for this compound. 
Zorbax CN is a polar bonded silica formed by bonding cyanopropyl 
groups to the surface of silica. A 10 cm column packed with 51, M 
material was used for the investigations outlined below. Employing 30% 
pH7.0 phosphate buffer (. 01M), 70% acetonitrile as eluant, tamoxifen 
and desmethyltamoxifen were quite well retained (k' = 10.8 and 4.4 
respectively). This pH was used to try to suppress the ionization of 
the solutes; increasing the pH even further would probably have caused 
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rapid column deterioration. The two compounds were therefore well 
separated under these conditions, but the tamoxifen peak in particular 
was quite broad. Lowering the pH of the mobile phase to 3.0 was tried 
next, in order to chromatograph the two compounds in their ionized 
form. With a mobile phase of 80% acetonitrile, 20% pH3.0 . 01M buffer 
tamoxifen and desmethyltamoxifen eluted quite quickly (k' = 2.5 and 2.2 
respectively), but they were only partially resolved. The addition of 
SDS or HS to this eluant decreased the retention of the two compounds. 
The peaks were quite narrow but not separated. Since the addition of 
pairing ions had decreased the retention of tamoxifen and its 
metabolite, it was decided to try using a pairing ion at a different 
solvent composition. The aim was to choose a system which would retain 
tamoxifen and desmethyltamoxifen in the absence of a pairing ion, such 
that addition of a suitable pairing ion would decrease the retention 
and hopefully sharpen up the peaks. With 60% acetonitrile in the 
mobile phase k' for tamoxifen and desmethyltamoxifen was 7.5 and 6.4 
respectively, but these k' values increased to 10.9 and 11.1 
respectively on the addition of 1OmM heptane sulphonate to the eluant, 
and very little separation of components was achieved. The results of 
all these mobile phase compositions on the chromatography of tamoxifen 
and desmethyltamoxifen are summarised in Table 8. 
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None of these eluants gave satisfactory peak shape and retention 
so it was decided to try a reverse phase column but with a shorter 
alkyl chain length than the C18 (ODS) columns tried before. 
A C5 silica column with 5UM material was used frst. Initially a 
mobile phase consisting of 80% acetonitrile 20% pH3 . 01M phosphate 
buffer was tried, conditions intended to bring the two (basic) 
compounds off fairly quickly. The peaks were quite well retained (k' '. 
5) and although they were fairly well resolved, the peak shape was 
poor. The addition of 1OmM HS to the mobile phase decreased the 
retention time, and sharpened up the peaks. The chromatograms obtained 
under these two sets of conditions are shown in Figure 23. Attempts to 
improve the chromatography included raising the pH of the buffer, 
lowering the pairing ion concentration, and reducing the acetonitrile 
content of the mobile phase. The details and results of these 
alterations to the eluant composition are shown in Table 9. None of 
these conditions gave a better peak shape and resolution than when 
using the conditions outlined in Figure 23, ie a mobile phase 
containing 80% acetonitrile 20% pH3, O. 1M phosphate buffer. 
The separation of these two peaks was not quite complete under 
such conditions, and they were quite close to the 'solvent peak' so it 
was decided that another column might be more suitable. (However if no 
improvements on these conditions were found the method described above 
was sufficiently good that it would be worth trying some extracts from 
plasma spikes using it). 
A reverse phase column with a slightly longer alkyl chain was 
tried nexts in an attempt to increase the retention of the tamoxifen 
and desmethyltamoxifen, without peak shape suffering too badly. A 10 
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Fiqure 23 Chromatograms of tamoxifen and desmethyltamoxifen 
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cm, 5UM, C8 modified silica column was used. A mobile phase of 80% 
acetonitrile 20% . 01M pH3 phosphate buffer retained the two peaks more 
than using C5 silica under the same conditions (k' now -. 5-6). The 
addition of 1OmM HS to the eluant decreased retention. Baseline 
resolution between tamoxifen and desmethyltamoxifen was now obtained. 
W707. &A Oz H5 
Lowering the acetonitrile concentration to 20mM also gave good 
resolution, reasonable peak shape and suitable retention. 
Chromatograms obtained under both sets of conditions are shown in 
Figure 24. The results of these changes in eluant composition are 
shown in Table 10. 
Under both sets of conditions (shown in Figure 24), suitable 
retention and peak shape and adequate resolution was obtained. Using 
80% acetonitrile and 10 mM heptane sulphonate gave slightly more 
efficient peaks. At this stage of the project several other structural 
analogues of tamoxifen became available, including the 4-hydroxy 
metabolite. The structures of these compounds along with their 
retention under the conditions described in Figure 24 are shown in 
Table 11 (conditions (a)). The results showed that whilst it was 
possible to separate tamoxifen from the two metabolites using the 
method described above, it was not possible to separate the two 
metabolites from each other. It was also found that all of the 
structural analogues had short retention times, and most of them were 
not resolved from the two metabolites. As the metabolites were now 
available, an additional requirement for the project was to separate 
4-hydroxytamoxifen, as well as the parent drug and its N-desmethyl 
metabolite and it was therefore considered necessary to investigate 
additional HPLC conditions. 
i 
Several variations in mobile phase composition were tried; 
/ 
B", est, 
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Variable Print Quality 
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Figure 24 Specimen chromatograms of tamoxifen and desmethyltamoxifen 
on C-8 silica (10cm x 5mm) 
Peak identification 1= desmethyltamoxifen 
2= tamoxifen 
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Table 11 The retention of structural analogues of tamoxifen under the 
HPLC conditions described, on a C8 silica column. 
Compound Structure 
tamoxifen CH 
N CH 2 
CH 
20 
Ph Ph 
CH 3 Ph -----, C 2H5 
desmethyl tamoxifen 
CH 3,, 
N CH CH 0 Ph, Ph 
--" 
22 
H, Ph"---, t 
2H5 
4-hydroxy tamoxifen 
CH 
3, 
CH /N 
CH 2 CH 20 
Ph Ph 
3c2H5 
HO 
k' conditions(a) k' conditions (b) 
1.9 2.2 
1.4 1.0 
1.3 1.4 
'trans clLomiphene' 
C2H5, 
N CH 2 CH 20 Ph Ph 
25 
Cis/trans cLomiphene 
ICI 99311 CH 
N CH 2 CH 20 Ph. Ph CH "' C -'Ph 3 
ICI 139331 C2H5, 
N CH CH 0 Ph Ph CH 322 
HO ýýCH 3 
ICI 138784 CH 
N CH CH 0 Ph 
CH 22c2H5 
HO c2H5 
ICI 129817 CH 3, 
CH '- 
N CH 2 CH 20 Ph CH3 
3 HO ýýo --\C H 
1.6 1.5 
1.8 (doublet) 1.5,1.8 (doublet) 
1.7 2.1 
0.9 0.33 
1.3 1.5 
1.3 1.4 
HPLC conditions (a) were 10 mM heptane sulphonate in 80% 
acetonitrile, 20'o' . 01 pH 3 phosphate buffer. 
(b) were 50 mM heptane sulphonate in 80% methanol 20% pH 3 
. 01 M phosphate buffer. 
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substituting methanol or n-propanol for acetonitrile, increasing the 
ionic strength of the buffer tenfold, and changing the nature and 
concentration of the pairing ion. SDS, sodium perchlorate and methane 
sulphonic acid were all tried. Only one set of conditions were an 
improvement on previous conditions, in terms of resolution and peak 
shape. This was the substitution of methanol for acetonitrile, along 
with an increase in the concentration of pairing ion (HS) from 1OmM to 
50MM. The chromatogram obtained under these conditions is shown in 
Figure 25. The structural analogues of tamoxifen were also 
chromatographed under these conditions and their retention is detailed 
in Table 11 (conditions b). The results show that only ICI 139331 is 
separated from the three compounds of interest, and this is close to 
the solvent front. None the less it was thus decided to attempt to use 
these HPLC conditions to measure plasma spikes of tamoxifen along with 
the two metabolites, and to include ICI 139331 as a possible internal 
standard. 
Application to plasma samples. 
Suitable HPLC conditions having been obtained for the separation 
of tamoxifen and its two major metabolites it was decided to try to 
find a suitable sample preparation procedure. Previous assays 
[Mendenhall 1978, Daniel 1979, Adam 1979] all used a single ether 
extraction, though an ICI unpublished method [Scales 1981] used a 
single 1.5% amyl alcohol in heptane extraction. 
Extraction studies were undertaken on control plasma spiked with 
-1 
200 ng ml tamoxifen and both available metabolites. Both ether and 
1.5% amyl alcohol in heptane proved suitable, when using 1M aqueous 
ammonium hydroxide to raise the pH. Dichloromethane and 1.5% amyl 
-11.2- 
I- 
Figure 25 Specimen chromatograms of tamoxifen and 
metabolites on C-8 silica 
2 
Column C-8 silica 50 10cmx5mm 
Eluant 50mM heptane sulphonate 
in 80',, methanol 20% 
0.01M pH3 phosphate 
buffer 
Flow rate 1.5ml/min 
Detector UV at 240nm 
Peak identification 
1= d6smethyltamoxifen 
2= 4-hydroxytanioxifen 
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alcohol in cyclohexane were also tried, but these gave a largesolvent 
f ront. Of all the solvents tried ether gave the clearest solvent 
front, and high recovery (%80%). Back extraction into acid did lessen 
the solvent front, but recoveries of tamoxifen were < 30%. 
Precipitation of plasma proteins with acetonitrile, methanol or 
perchloric acid prior to adding aqueous ammonia followed by ether 
extraction also gave recoveries of < 30%. It was decided therefore to 
use a sample preparation procedure involving; addition of 1 ml of 1M 
ammonium hydroxide, extraction with 10 mls of ether, evaporation to 
dryness, and injection of 20 ul from the sample redissolved in 100 Ul 
of eluant, onto the HPLC. 
Further validation of the procedure outlined above was carried out, on 
20 cm CB-silica columns, using standard curves of tamoxifen (TX), 
desmethyl tamoxifen (DMTX) and 4-hydroxytamoxifen (OHTX) spiked into 
control plasma. 
-1 
The standard curves (on days 1-4) were over the range 
25 - 300 ng ml , and were plots of peak height of analyte against 
plasma concentration spiked. The results are shown in Table 12. 
Despite the good standard curves achieved so far it was decided 
that the variation in recoveries (Table 12) could lead to imprecise 
results when using plasma from a variety of patients. The other 
structural analogues of tamoxifen available (Table 11) were thus 
considered as suitable internal standards. Only ICI 139331 was 
separated from all three analytes, and this came off so quickly it 
could be lost in the solvent front. The alternative was to consider 
assay only of tamoxifen and the major metabolite desmethyl tamoxifen. 
The levels of 4-hydroxy-tamoxifen are much lower [Addam, 19791, usually 
by a factor of 20 or more. The analogue ICI 129817 was therefore tried 
as a possible internal standard for tamoxifen and desmethyl tamoxifen 
-114- 
assay. It differs structurally from tamoxifen, by-the addition of a 
hydroxyl group and a methyl group to different aromatic rings, and is 
not therefore likely to be a metabolite. The sample preparation 
approach 
Tabl e 12 Correlation coefficient and recovery of tamofixen and 
metabolites from standard curves (no internal standard) 
Correlation coefficient 
%Recovery (200ng ml 
level) 
DMTX 4-OHTX TX 
day 1 . 986 . 991 . 982 
2 . 995 . 993 . 999 
3 . 997 . 998 . 999 
4 . 986 . 998 . 990 
day 1 68 62 84 
2 112 125 70 
3 78 86 84 
4 68 83 84 
outlined above was used to generate further standard curves, all of 
which gave correlation coefficients of 0.98 or above. Typical examples 
of a standard curve of tamoxifen and desmethyltamoxifen are shown in 
Figure 26, using a 20 cm C-8 silica column. 
Typical chromatograms of plasma extracts are shown in Figure 27. 
The method was also checked out on the plasma of patients undergoing 
tamoxifen therapy. This pharmacokinetic study did not specifically 
form part of this research programme. However, the method developed 
has allowed the assay of over 100 samples for desmethyltamoxifen and 
tarnoxi fen. 
1.8 
Fiqure 26 
Standard curves of 
(a) desmethyltamoxifen 
(b) tamoxifen 
extracted from plasma 
0.9 
0 
Peak height 
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Plasma concentration(ng/ml) 
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(ng/ml) 
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Figure 27 Specimen chromatograms of tamoxifen and desmethyltamoxifen 
extracted from plasma using ether 
Column C-8 s ilica 5um 
20cr1r: x 5mm 
Eluant 80% methanol 20% 
pH3 phosphate buffer 
containing '50mM 
heptane sulphonate 
Detection UV at 240nm 
Flow rate 1-5ml/min 
Peak identification 
1= desmethyltamoxifen 
2= ICI 129817 (internal 
standard) 
3= tamoxifen 2 
(1) 
U 
(o 
o 
ccr 
1 
I! ' 
3 
2 
L- 
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C) Investigation of underlying mechanism of the separation. 
The effect of sodium heptane sulphonate concentration in the 
eluant (80% methanol, 20% pH3.0, . 01M phosphate buffer), on the 
retention of the analytes on C-8 silica was studied systematically. 
The results are shown in Table 13. The concentration of the sodium 
phosphate buffer was also increased and decreased by a factor of 10 (at 
50 mM heptane sulphonate). This did not have any significant effect on 
retention, so it is the change in HS and not sodium concentration that 
regulates the retention of tamoxifen and its metabolites under these 
conditions. These results will be discussed in the next section. 
Table 13 The effect of heptane sulphonate concentration in mobile 
phase on the retention of tamoxifen and metabolites on a C-8 silica 
column. 
Concentration of heptan k' k' k' 
sulphonate in eluant DMTX OHTX TX 
mm 
50 1.1 1.4 2.4 
20 1.7 2.3 4.1 
10 2.8 3.8 6.3 
5 4.2 5.6 9.6 
2 7.2 9.7 16.2 
1 8.8 11.7 19.9 
0 13.4 17.8 30.2 
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d) Discussion of Results. 
The HPLC system developed gives short retention times for 
tamoxifen and its two main metabolites. All three compounds are fully 
resolved (Figure 25), within a run time of 5 minutes. The simple 
sample preparation approach described allows determination of tamoxifen 
-1 
and both major metabolites down to 25 ng ml with or without the 
use of an internal standard. 
However, the use of the internal standard should allow for more 
precise measurements when handling samples from different patients. 
The precision of the method was checked using spiked standards, and 
gave a C. V. of - 6% at the 200 ng/ml level for both tamoxifen and 
desmethyl tamoxifen. The 4-hydroxymetabolite does not interfere with 
the assay as it is not present at levels greater than one twentieth 
those of tamoxifen [Adam 1979, Daniel 1979]. The drug 'clomiphene, has 
a retention time similar to ICI 129817, and might be a useful 
alternative internal standard. 
The HPLC conditions finally developed for the assay are unusual. 
Tamoxifen is a lipophilic basic drug and high concentrations of 
methanol or acetonitrile, along with low pH, were needed to elute this 
compound from RP columns. Even then peak shape was not satisfactory. 
The addition of HS shortened retention times, rather than the expected 
lengthening. More importantly, peak shape and therefore resolution was 
improved. For optimum separation of tamoxifen and metabolites the 
alkyl chain length of RP columns was found to be important. With C-18 
chain length the compounds were too well retained, with C-5 chain 
length they were not quite separated, but with C-8 silica separation 
and retention were adequate. The concentration of HS, added to the 
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eluant as an ion-pairing agent was critical for the regulation of the 
retention of the analytes. Instead of the expected increase in 
retention of tamoxifen and metabolites, the addition of HS caused a 
decrease. This is possibly caused by solute/HS ion pairs formed in the 
mobile phase competing with HS for retention sites on the stationary 
phase. A plot of the log retention on C8 silica versus eluant heptane 
sulphonate concentration is shown in Figure 28. 
The method has proved suitable for the determination of tamoxifen 
levels in patients on a multiple dose study, taking 20 mg of tamoxifen 
daily. Results are shown in Figure 29. 
3.4 Enhancement of detector response using UV absorbing pairing-ions 
Ion-pair HPLC operated in the normal phase mode allows the use of 
a highly UV-absorbing or fluorescent pairing-ion to enhance the 
detection of non responding molecules. Crommen, 1977, has shown this 
using naphthalene sulphonate coated onto silica. The same group has 
also shown the advantage of using DMAS as a pairing-ion for ion-pair 
extraction studies. DMAS shows a much greater UV and fluorescent 
response than naphthalene sulphonate [Westerlhd, 1973a and Q. 
Coating of DMAS onto different columns was therefore investigated. 
a) Ion-pair extraction studies using DMAS 
The W-absorption spectrum of DMAS is shown in Figure 30. The 
absorption maximum occurred at 264 nm. Extraction experiments were 
carried out using 1 mM DMAS in phosphate buffer (pH3.0) as the aqueous 
phase, and dichloromethane as the organic phase. The phase volume 
-120- 
Figure 28 Double log plot of k1for tamoxifen and metabolites 
against heptane sulphonate concentration in eluant 
HPLC conditions as on Fig. 27 
x= tamoxifen 
"= 4-hydroxytanoxifen 
s3 = desmethyltamoxifen 
loa k/ 
1.0 
I. / 
log heptane sulphonate conc. in eluant 
0 I. u 
-. J- 
Figure 29 Tamoxifen and desmethyltamoxifen plasma levels in patients 
undergoing tamoxifen therapy 
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Figure 30 Absorption spectrum of DMAS (0.007mM'in 0.01M TFA) 
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ratio was 1: 2, aqueous : organic (2.5 ml and 5.0 ml respectively). 
Each test compound was made 10 UM in the aqueous phase, before shaking 
with the organic phase. All extractions were carried out at room 
temperature. The UV absorbance at the maximum closest to 264 nm, in 
the organic layer, was determined. The results are shown in Table 14, 
using a selection of model compounds as test solutes. 
Table 14 Extraction into dichloromethane, of model compounds as ion- 
pairs with DMAS 
Compound 
DMAS alone 
propranolol 
atenolol 
tamoxifen 
Absorbance at 
at -%. 265m 
0.15 
0.52 
0.18 
0.38 
S-carboxymethylcysteine (SCMC) 0.32 
S-carboxyethylcysteine (SCEC) 0.33 
cetrimide 0.44 
tetrabutylammonium (TBA) 0.63 
tetrapentylammonium (TPA) 0.65 
tetrahexylammonium (THA) 0.54 
benzyltrimethylamr. ionium (BTEA) 0.45 
Absorbance - DMAS 
Background 
0.37 
0.03 
0.23 
0.17 
0.18 
0.29 
0.48 
0.50 
0.39 
0.30 
All the model compounds (except atenolol), increased the 
extraction of DMAS into the organic phase. The shapes of the UV 
spectra were virtually identical to that of DMAS alone. None of the 
model compounds above would be expected to show a UV absorption maximum 
at -. 265nm, and the absorption spectra demonstrated that ion-pair 
extraction is therefore taking place. 
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Studies to investigate the partition of DMAS into dichloromethane, 
containing small amounts of alcohol, were undertaken. No cationic 
solutes were present, so the studies thus served to show the background 
extraction of DMAS. The aqueous phase was 1 mM DMAS in O. 1M phosphate 
buffer (pH 3.0), and the phase volume ratio was 1: 2 aqueous : organic 
phase. The results are shown in Table 15. 
Tabl e 15 Extraction of DMAS into dichloromethane, containing alcohol 
Absorbance at 265nm 
% alcohol Isopropanol n-butanol n-pentanol 
0 0.13 0.13 0.13 
1 0.17 0.19 0.12 
2 0.20 0.29 0.16 
5 0.35 0.88 0.78 
10 1.10 2.80 2.70 
Two model compounds (propranolol and cetrimide) were used to test 
the extraction of ion-pairs with DMAS at different solute 
concentrations. For propranolol, the aqueous phase was 2.5 mM DMAS in 
. 01 M TFA, containing different propranolol concentrations, and the 
phase volume ratio was 1: 2, aqueous : organic. The results are shown 
in Table 16. 
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Table 16 Extraction of propranolol-DMAS ion-pair into dichloromethane 
Concentration of propranolol in 
aqueous phase (Uglml) 
0.0 
0.2 
0.5 
1.0 
2.0 
5.0 
10.0 
Absorbance at 265 nm 
0.09 
0.10 
0.14 
0.19 
0.33 
0.80 
1.70 
For cetrimide, the aqueous phase was 0.1 mM DMAS in 0.1 M 
phosphate buffer (pH 3), and the phase volume ratio was 112, aqueous 
organic phase. The results are shown in Table 17. 
Table 17 Extraction of cetrimide - DMAS ion-pair into dichloromethane 
Concentration of cetrimide in 
. 
aqueous phase (ug/ml) 
0 ug/ml 
2 ug/ml 
4 ug/ml 
Absorbance at 265 nm 
0.05 
0.25 
0.43 
The results of these experiments are discussed later (section 
3.4c). 
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b) Loading of aqueous stationary phases containing DMAS onto HPLC 
col umns. 
Throughout all stationary phase experiments, the column, injector 
and solvent reservoir were thermostatted at 250C. Two different 
techniques were used to coat an aqueous solution of DMAS onto normal 
phase columns. In both cases the dead volume of the column was 
measured, either using the refractive index peak caused by injection 
disturbances, or by measuring the retention volume of toluene 
(essentially unretained under the conditions used). The volume of 
aqueous phase held on the silica surface was thus calculated by the 
drop in dead volume caused by deposition of stationary phase. The 
amount of DMAS held on the column was determined, after each experiment 
by washing off the stationary phase with acetone or methanol, 
collecting the washings, evaporating to dryness, redissolving in water 
and then measuring the concentration of DMAS by UV spectroscopy. 
(1) Spherisorb 5uM- silica 10 cm x5 mm. 
The first coating technique attempted was the pumping of 1: 3, 
acetone: 1 mM DMAS in phosphate buffer pH 3 (0.01 M). Approximately 25 
ml was pumped through at 2 ml/min. The acetone was then washed off 
using 100 ml of hexane saturated with the aqueous phase. The mobile 
phase was then changed to 5% n-butanol in dichloromethane, saturated 
with stationary phase, and the system was left overnight with solvent 
recycling. The dead volume of the column was estimated, using the 
refractive index peak, before coating, but had not changed after the 
attempt to coat stationary phase. Injections of propranolol did not 
show any peaks. The amount of DMAS held on the column was measured, 
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as described earlier in this section, but none was recovered. The 
experiment was repeated using 0.1 mM DMAS in the stationary phase, and 
a mobile phase of 5% n-pentanol in dichloromethane, but again neither 
dead volume calculations, nor washing and collecting DMAS, revealed any 
aqueous phase held on the column. 
The column was thoroughly washed, and tested using the conditions 
described in section 2.3 of this thesis, and gave approximately 8000 
theoretical plates. The column was therefore still performing very 
well and a second coating technique was tried. This technique involved 
direct injection of 50 Ul aliquots of the aqueous stationary phase onto 
the column. The mobile phase (up to 5 percent alcohol in 
dichloromethane) was always pre-saturated with stationary phase. 
Repetitive injections were carried out until the detector signal (UV at 
265 nm), went off the scale. This indicated that the column was now 
saturated with stationary phase, such that UV-absorbing DMAS was now 
eluting (NB the detection signal would also have been disturbed by 
droplets of water in the detector cell). 
The first attempt to coat silica used 0.1 mM DMAS in pH 3,0.1 M 
sodium phosphate buffer as the stationary phase, and 2% pentan-1-ol at 
2 ml/min as the mobile phase. Saturation of the column occured after 
14 x 50 til injections (0.7 ml) of aqueous stationary phase had been 
coated. Once the baseline had settled, propranolol and cetrimide were 
injected, but no peaks were seen. The mobile phase was changed to 5% 
pentan-1-ol in dichloromethane, but again no peaks were seen. The 
column was washed with 20 ml acetone, and the washings collected. (The 
solvent lines had been prewashed with acetone, so that only stationary 
phase coated on the column was collected. ) The washings were 
evaporated to dryness, redissolved in 5.0 ml water, and the amount of 
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DMAS collected was determined spectrophotometrically from standards. 
Calculations showed that 75 n moles of DMAS had been held on the 
column, which would be equivalent to 0.75 ml of 0.1 mM DMAS. 
A second attempt to coat this column using the same stationary 
phase was attempted. On this occasion the mobile phase during coating 
was 5% butan-1-ol in dichloromethane at 2 ml/min. Column saturation 
occurred after 18x 50 ul injections of stationary phase (ie 0.9 ml). 
The dead volume of the column was determined before and after coating, 
using toluene as a non-retained solute. This showed a drop from 1.45 
ml to 0.75 ml during coating. 
The following model compounds were injected once the baseline had 
stabilised, propranolol, cetrimide, benzy1trimethyl ammonium bromide, 
and tetrahexylammonium bromide, but no peaks were seen. The eluant was 
changed to 5% butan-1-ol in dichloroethane, but again no peaks were 
observed. The stationary phase was washed off the column with acetone, 
collected and measured, as described earlier. It was found that 169 n 
moles of DMAS had been coated, equivalent to 1.7 ml of aqueous 
stationary phase. 
The third attempt to coat an aqueous stationary phase involved a 
higher concentration of DMAS (1 mM) in O. 1M pH 3 phosphate buffer. The 
mobile phase during coating was 5% butan-1-ol in dichloromethane at 2 
ml/min. The column was saturated after 16 x 50 lil injections of 
stationary phase. The dead volume of the column dropped from 1.7 to 
0.8 ml during coating. However, the amount of DMAS in the mobile phase 
caused such a high background absorbance, and an unsteady baseline, 
that it was not possible to perform any injections of model compounds. 
The eluant was changed to 2% butan-l-ol and to 5% pentan-l-ol in 
I -7 
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dichloromethane, but the problems with the baseline still occurred 
intermittently and no peaks were seen for propanolol, cetrimide, 
tetrabutyl ammonium, tetrapentyl ammonium or tetrahexyl ammonium bromide. 
The column was washed with acetone and the amount of DMAS held on the 
column was measured as before. It was found that 2.3 m moles-of DMAS 
were coated (equivalent to 2.3 mls of aqueous stationary phase). 
No further attempts to coat aqueous stationary phases containing 
DMAS, onto silica columns were tried. 
Zorbax-CN 5 jiM 10 cm x5 mm. 
The direct injection method, for coating stationary phases was 
also tried on a Zorbax-CN column. The stationary phase was 1 mM DMAS 
in . 01M pH 3 phosphate buffer, and the mobile phase was dichloromethane 
at 2 ml/min. Column saturation occured after 7x 20 Ul injections 
(0.14 ml). The dead volume of the system only dropped from 1.3 to 1.2 
ml during coating. The baseline took several days to settle and even 
then only a few injections could be made. Tetrapropyl-ammonium, 
tetrahexylammonium and tetrabutylammonium bromide, cetrimide, 
propranolol, tamoxifen and SCMC were all injected, but no peaks were 
seen. The column was then washed with methanol and the amount of DMAS 
held on the column was determined as previously described. It was 
found that 0.6 m moles of DMAS has been held on the column, equivalent 
to . 06 ml of stationary phase. 
(3) Lichrosorb diol 5 VM 10 cm x5 mm. 
The direct injection technique was also used in an attempt to coat 
an aqueous stationary phase on Lichrosorb diol. The aqueous phase was 
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1 mM DMAS in . 01 M pH 3 phosphate buffer, and the eluant during coating 
was dichloromethane. Saturation occurred after 15 x 30 ul injections 
(0.45 ml). The dead volume dropped from 1.5 to 1.2 ml during coating. 
The following model compounds were injected; propranolol, SCMC 
cetrimide and tetrabutyl, tetrapentyl and tetrahexyl ammonium bromide. 
No peaks were observed. The stationary phase was washed off the column 
and showed that 973 n moles of DMAS had been held on the column 
(equivalent to 1.0 ml of aqueous stationary phase). 
C) Discussion of results 
Table 14 shows that DMAS is capable of extracting the model 
compounds into dichloromethane. This extraction data can be used to 
calculate the amount of DMAS extracted into the organic phase, and 
assuming each model compound extracts as a 1: 1 ion-pair, also gives the 
amount of solute extracted. We can then calculate (by difference) the 
amount of model compound left in the aqueous phase. Using this data we 
can calculate conditional extraction constants from equation (8). 
E C 
BP BP org 
c+ c 
B aq A aq 
For each solute the aqueous phase before extraction contained 1.0 
mM DMAS and 10 UM of solute. The concentrations of ion-pair in the 
organic phase are shown 
and the concentration of 
as C+ The ratio 
B aq 
fact the distribution ral 
as C organic for each solute in Table 18, 
BP 
solute left in the aqueous phase is presented 
C /C + is also shown (this is in 
BP org B aq 
; io shown by equation (5)). This value is then 
divided by 0.001. the molar concentration of DMAS in the aqueous phase 
(the very small amount of DMAS does not significantly change the 
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concentration present before extraction). 
Table 18 Calculation of conditional extraction constants 
c c+ c E 
BP org B BP orq BP 
UM UM C+ Moles/litre B aq 
Propranolol 2.6 7.4 0.35 350 
Atenolol 0.2 9.8 0.02 20 
Tamoxifen 1.6 8.4 0.19 190 
scmc 1.2 8.8 0.14 120 
SCEC 1.3 8.7 0.15 150 
Cetrimide 2.0 8.0 0.25 250 
TBA 3.3 6.7 0.49 490 
TPA 3.5 6.5 0.54 540 
THA 2.7 7.3 0.37 370 
BTEA 2.1 7.9 0.27 270 
The conditional extraction constant can then be used to calculate 
phase capacity ratios W, using equation (10) 
Vs 
Vm E [P laq 
BP 
except that the conditional extraction constant E 
BP 
is 
substituted for the extraction constant E The concentration of 
BP 
pairing ion in the aqueous phase is given by EP laq, and the phase 
volume ratios in the column are determined experimentally using dead 
volume calculations. Some results from section 3.4 bl can be used as 
an example. The amount of stationary phase injected, before saturation 
of the column occurred, can be used as Vs, and the dead volume of the 
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system after coating as Vm, the amount of mobile phase in the column. 
When coating with 1 mM DMAS, Vs was 0.8 ml and Vm was 0.8 ml, and when 
using 0.1 mM DMAS as aqueous stationary phase the value of Vs was 0.9 
and Vm was 0.75 ml. These values have been used along with equation 
(10) to predict k' values from conditional extraction constants. These 
are shown in Table 19. 
Tabl e 19 k' values on silica predicted from conditional extraction 
constants 
Compound E 
Propranolol 
BP 
350 
Atenolol 20 
Tamoxifen 190 
scmc 140 
SCEC 150 
Ce)ýtrimide 250 
TBA 490 
TPA 540 
THA 360 
BTEA 270 
k' (0.1 mM DMAS) k' (1 mM DMAS) 
34 
600 
63 
86 
80 
48 
24 
22 
32 
44 
2.9 
50.0 
5.3 
7.1 
6.7 
4.0 
2.0 
1.9 
2.7 
3.7 
These predicted k' values are based on several assumptions: - 
that 1: 1 ion pairs are formed 
that phase volume ratios are correct 
that the silica support plays no role in retention 
that the absorbance at 265 nm in the organic phase is 
all due to DMAS 
that the molar absorbance of DMAS in dichloromethane is 
the same as in water 
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The k' values indicate that the model compounds chosen should 
elute from the column in a fairly short time. However, in practice no 
peaks were seen. 
Furthermore, the batch extraction experiments used dichloromethane 
as the extracting solvent, whereas the chromatographic experiments 
employed small percentages of alcohols in the eluant. This would be 
expected to shorten the retention of the compounds. The extraction 
data (shown in Table 15) for DMAS, showed that only a small percentage 
of alcohol (up to -. 5%) could be used in the eluant, before the amount 
of DMAS extracted gave an unacceptably high 'background' reading. It 
was therefore not worthwhile to attempt to shorten retention by 
increasing the eluant polarity. 
jý 
Of the coating techniques tried, only direct injection of 
stationary phase coated the aqueous phase onto the column. There were 
also certain practical difficulties with these experiments. Columns 
had to be left for long periods to equilibrate (often 48 hrs), and even 
then, baselines were noisy and drifted. These problems were not cured 
by measures such as careful thermostatting of column, injector and 
solvent reservoir; recycling eluants and pre-saturation of eluants with 
stationary phase. In general stable baselines were obtained for only 
short periods of time. 
Attempts to estimate the amount of aqueous phase coated on the 
column, showed broad agreement between the amount injected before 
saturation was reached and the amount calculated from the drop in dead 
volume. However, in each case the amount of DMAS washed off the column 
was greater than the estimated volume of aqueous phase. This indicated 
that DMAS was being stripped from the eluant (which was pre-saturated). 
t'i 
-134- 
This would have been caused by adsorption of DMAS by the column 
surface, or association of DMAS in the aqueous phase. Polar bonded 
phases (cyano and diol) were evaluated in order to reduce the effect of 
the silica surface on the separation, but clearly silica was able to 
absorb a greater volume of stationary phase than these two columns. 
3.5 Attempts to separate enantiomers using chiral pairing-ions 
The separation of enantiomers using chiral derivatization reagents 
or columns has proved a successful means of overcoming a difficult 
analytical problem. In principle the formation of ion-pairs with 
chiral pairing-ions is very similar to the former approach, and would 
therefore offer a simpler approach in that, lengthy derivatization 
reactions could be avoided. 
a) Cationic model compounds 
A range of optically active pairing ions were used as model 
compounds. These are shown, along with their structural formulae and 
the formulae of the pairing ions, in Table 20. Most compounds were 
available as racemates, but for some both the pure d- and 1- forms were 
obtained. Initial experiments were carried out on a 10 cm 5pM Hypersil 
ODS column. The mobile phase was methanol/. 05M sodium acetate buffer 
(pH 4.0). The effect of modifier/aqueous buffer ratios on retention, 
in the absence of pairing ion was studied. The results are shown in 
Table 21. Each compound was monitored at the wavelength of its maximum 
UV absorbance. 
For each compound, a solvent composition at which it was not well 
retained was chosen (k' < -. 2). Sodium I-camphor sulphonate was added 
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Table 20 Model compounds for chromatography of enantiomers using 
chiral pairing ions. 
Name Formu 1a 
, e, OCH CH. CH NH. CH. (CH 2 2* 
Propranolol 00 OH 00: 03 
Tetramisole 
/- Q-\ 
Nis 
ýCH 2' CH CH 2« NH. CH (CH 3)2 
Atenolol 0 OH 
CH 2* COAH 2 
O. CH 2 CIH-CH 2* NHCH. (CH 3)2 
Practolol 
0 
OH 0 
NH. CO, CH 3 
H2* CH CH 2 NH. CH, (CH 3)2 
Alprenolol CH 2* CH = CH 2 
CH 013 
C (, H. NH. UH 
Ephedrine 0 
Table 20 cont. over leaf 
Table 20 cont. 
Adrenaline 
Nor adrenaline 
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oý CH-CH7-NH-CH 3 
0 
OH 
1i022-, CH r NH 
011 
CO 
OH 
CH 
13 
129830/1 00 LH 2 0- C-COOH 
Cl 
CF 3 
Sodium Camphor- 
10-sulphonate 
Sodium 3-Bromo 
camphor-10- 
sulphonate 
-A nanemethylamine 
hydrochloride 
CH 3 CH 3 
CH ; FSO-3 Na E0 
CH 3 CH 3 
CH -SO -Na 23 
0 
Br 
c3 
CH -A 4-- HCI 23 
CH3 
H3 
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to the eluant, in an attempt to increase the retention of the solutes 
by ion-pairing. Propranqlol, atenolol, practolol, alprenolol, 
ephedrine, adrenaline and nor-adrenaline were all run with a solvent 
composition of 70/30 methanol/buffer with 20 mM 1-camphor sulphonate 
added. However, for all compounds retention decreased slightly with 
the addition of pairing ion. At a solvent composition of 50/50 
methanol /buffer, the addition of 20 mM 1-camphor sulphonate caused a 
small decrease in the retention of atenolol, practolol, ephedrine, 
adrenaline and nor adrenaline. Finally, using a solvent composition of 
30/70 methanol buffer, the addition of 20 mM I-camphor sulphonate to 
the eluant caused a decrease in the retention of atenolol, practolol, 
adrenaline and nor-adrenaline. No separation of enantiomers was 
achieved. This is not suprising, since it would only be expected if 
retention increased, with increasing concentration of pairing ion, ie 
when conventional ion-pairing was taking place. 
Further studies were carried out using d- and I- propranolol, 
using both d- and 1- sodium bromocamphor sulphonate, and also using 
sodium d-camphor sulphonate as pairing ions. Different (less 
hydrophobic) column packings were tried - Hypersil SAS, phenyl modified 
silica, lichrosorb diol and silica gel. In all experiments the 
addition of pairing ion either decreased retention slightly, or did not 
alter it. Variation of solvent, pH and ionic strength had no effect. 
In no instance was there any separation of enantiomers. In most cases 
however, the addition of pairing ion did cause an improvement in peak 
shape (an increase in number of theoretical plates). 
Anionic model compound. 
ICI 12930/1 was available as both the d- and I- isomer. The 
-139- 
structure of this compound is shown in Table 20. It is an acidic 
molecule. with a pKa, of 2-3 (ICI internal report). Attempts were made 
to separate the enantiomers on a 10 cm Hypersii ODS column using 3- 
aminomethylpinane hydrochloride as the pairing ion. 
The mobile phase consisted of . 05 M sodium acetate buffer, pH 5.0, 
and either methanol or acetonitrile was the organic modifier. The 
buffer/modifer ratio chosen was one where 129830/1 was not well 
retained (k' <2), such that, potentially, retention could be increased 
by the addition of a suitable pairing ion. Results are shown in Table 
22. 
Table 22 The effect of pairing ion on the retention of ICI 129830/1 
Eluant k' 
50/50 acetonitrile/sodium acetate buffer 0.5 
ditto plus 5 mM 3-aminomethylpinane 1.9 
ditto plus 25 mM 3-aminomethylpinane 5.8 
60/40 methanol/sodium acetate buffer 2.1 
ditto plus 5 mM 3-aminomethylpinane 8.8 
Both the d- and 1- isomers of 3-aminomethylpinane were used, but 
the results were identical. Other conditions are given in the text. 
The results show that ion-pairing is taking place, causing an increase 
in the retention of 129830/1. However, no separation of enantiomers 
occurred. 
C) Discussion of Results. 
The airn with the HPLC systems employed here was to set up RP ion- 
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pairing systems, where retention could be controlled (ie increased) by 
the addition of a suitable pairing-ion - in these cases optically 
active. Consequently, for each model compound, a solvent system 
whereby they were hardly retained was selected. The effect of adding 
an optically active pairing-ion was then 'investigated. Only a small 
number of optically active pairing-ions that do not absorb in the UV is 
available. As RP systems were being investigated a strong UV region 
absorbance would have excluded the use of many of the commercially 
available optically active pairing-ions. 
For ionic compounds (including the majority of drugs), sodium 
camphor-10-sul phonate (both d- and l-) and bromocamphor-10-sul phonate 
were investigated as pairing ions. In the RP systems tried, these 
particular pairing-ions were unable to increase the retention of the 
model compounds evaluated. This was probably due to the fact that the 
pairing-ion was not sufficiently lipophilic (cf earlier studies with 
propranolol HS or SDS). Consequently no separation of enantiomers was 
achieved under the conditions employed. 
For the anionic compound ICI 129830/1 it was possible to regulate 
the retention on a RP column, by the addition of d- or 1-3- 
aminomethylpinane as pairing-ion. Even so, the enantiomers could not 
be separated. This was probably because the asfyýetric centre in the A 
pairing-ion was not adjacent to the charged group on the ion. In 
addition, some of the groups on the assymetric carbon atoms of the 
solutes were small ie H CH , or CF , such that steric interaction 433 
could not take place between the pairing-ion and the model compound. 
oll. ,I 
CHAPTER 4 GENERAL DISCUSSION 
Fluorimetric assays for propranolol in biological fluid involving 
no clean-up, lack the specificity of an HPLC fluorimetric assay. 
Measurement of propranolol by GLC, though sensitive and specific, 
requires derivatization. The method described in Chapter 3.1 is both 
sensitive and specific and requires only a single solvent extraction 
step. The use of 215 nm excitation for fluorescence rather than 290 nm 
provides extra sensitivity. Methods described by Nygard 1979, Jatlow 
1979 and Taburet 1980, all use the higher wavelength but their standard 
curves only go down, at best, to 6 ng/ml body fluid. Lo (1980) and 
Mackichan (1980) both use the lower wavelength for excitation and 
report a limit of detection of 2 ng/ml and 0.5 ng/ml respectively. 
This is in good agreement with the work reported in Chapter 3.1, where 
a CV of 8.7% was obtained at 1 ng/ml, indicating that the limit of 
detection was 0.5 ng/ml or lower. 
All the previously reported HPLC methods used a 25 or 30 cm 
column, as opposed to the 10 cm column described here. Both Nygard 
(1979) and Mackichan (1980) used cyano columns in the ion suppression 
mode, Jatlow (1979) and Lo (1980) employed ODS columns at low pH, while 
Taburet (1979) used an ODS column with HS as a pairing-ion. The 
studies reported in Chapter 3.1 showed that at best the ion suppression 
mode gave a reduced plate height (h) of 10, using ODS at low pH gave at 
best h= 12, whereas for an ion-pair system using SDS (Figure 6) on h 
value of 5 was obtained. The method reported here thus shows efficient 
chromatography, sensitive specific detection, short run times, simple 
sample preparation, good recovery and excellent reproducibility. It 
also shows promise for the determination of other drugs structurally 
related to propranolol and also for metabolites of these compounds. 
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Further work could usefully be aimed at adapting this methodology to 
other beta-blocker drugs. 
The methods' described earlier (Chapter 3.2) for chloropromazine 
and metabolites are also specific, sensitive and reproducible enough to 
allow the determination of therapeutic levels of those compounds. This 
is in contrast with the GLC assays tried in this laboratory. In 
addition, excellent week-to-week constancy of retention times was 
found. 
Experiments to determine the effect of the pairing-ion on the 
retention of chlorpromazine and metabolites (Chapter 3.2c) indicated 
that the separation mechanism was adsorption rather than partition. 
Confirmation of this requires further non-chromatographic experiments, 
such as measurement of the amount of HS, methanol or water retained by 
the silica surface. The ion-pair extraction method described in 
Chapter 3.1c for SDS determination did not work for heptane sulphonate 
measurements, presumably due to its short chain length. Determination 
of the amount of pairing-ion held on the si lica column was thus not 
attempted. Silica columns are used to a much lesser extent than RP 
columns for trace drug determinations, as the latter are generally more 
suitable for polar compounds. The successful use of silica with an 
aqueous mobile phase described in Chapter 3.2 strongly suggests that 
analysts evaluate these HPLC systems for a wider range of applications. 
Tamoxifen has long proved a difficult drug to assay in biological 
fluids. For a single 40 mg dose, it is important to measure blood 
levels down to -2 ng/ml [Daniel, 1979]. Steady state levels (150-300 
ng/ml) are not reached until several weeks of daily oral dosing. The 
method described earlier (Chapter 3.3) is thus suitable for multiple 
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dose studies and therapeutic monitoring. The method is simple, quick 
and does not require conversion of tamoxifen to a fluorescent 
derivative. The N-desmethyl metabolite can be determined 
simultaneously. Another advantage of the method is that it has greater 
potential for automation. This is not possible when using the 
fluorescent derivatives as they are not stable for more than an hour. 
The short retention times described in Chapter 3.2 should be suitable 
for post-column on-line conversion of tamoxifen and metabolites'. This 
method has recently been described by Brown (1983) and would have 
advantages of both speed and sensitivity. 
The mechanism of the separation described for tamoxifen is not 
clear and is termed ion-pairing only because solute retention is 
controlled by the concentration of the oppositely charged sodium 
heptane sulphonate. In recent years there has been much disagreement 
about the exact nature of RP phase ion-pair HPLC. Several theories 
have been put forward, including ion-pair formation in the mobile phase 
[Horvath, 19771, dynamic ion-exchange [Terweij-Groen, 1978], and 
mechanisms based on a mixture of these such as ion-exchange desolvation 
[Hung, 19811. Sharp distinctions between these mechanisms cannot be 
made [Sorel, 19831. Indeed it is likely that no single theory can 
account for the mechanism of separation of the wide range of solutes 
using many different pairing-ions now described in the literature. 
This would appear to be exemplified by the tamoxifen assay described 
above where clearly, conventional theory (ie an increase in retention 
with increase in pairing-ion concentration) has not been observed. 
This does not prevent successful manipulation of the many variables 
associated with ion-pair HPLC. The retention studies in Chapter 3.2 
and 3.3 clearly demonstrate the ability of ion-pair HPLC to 
chromatograph compounds that do not give good peak shape when using 
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other modes of HPLC. The studies of the effect of mobile phase 
composition on retention (Chapter 3.1,3.2 and 3.3) also demonstrate 
the advantage of using a systematic approach to the development'of ion- 
pair HPLC systems. 
Historically the early development of HPLC by Schill and co- 
workers involved the use of stationary phases (both normal and RP) 
mechanically held onto supports. This requires very careful 
maintenance of stationary phases. The introduction of chemically 
bonded stationary phases was an important improvement particularly in 
the use of RP systems. Nonetheless, enhancement of detection (possible 
in the normal phase mode) provides a powerful incentive for attempting 
troublesome column loading techniques. However, despite the promise 
shown by DMAS in extraction studies (Chapter 3.4a), this author was not 
able to develop successful HPLC systems using coated aqueous stationary 
phases containing DMAS. Attempts to chromatograph model compounds were 
thwarted by the fact that only a small amount of alcohol could be used 
in the mobile phase, due to background extraction of DMAS. In 
addition, because DMAS was stripped from the eluant, probably by 
association, dissociation was probably also occurring on the column 
resulting in unstable baselines. It would appear therefore that DMAS 
is not suitable for column loading experiments. 
More recently another approach has been suggested as a means of 
detecting non-UV absorbing compounds. This involves the use of UV- 
absorbing or fluorescent pairing-ions in the mobile phase. Peaks that 
do not absorb at the selected wavelength are detected by the drop in 
absorbance at that wavelength [Small, 19821. This simple approach 
warrants further study for, certain types of analysis but is unlikely to 
prove generally successful bearing in mind the many and varied 
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difficult matrices, eg biological fluids, whiqh the analyst is called 
upon to work with. 
The separation of enantiomers is a very considerable but a very 
important task especially in regard to drug therapy. The use of a 
chiral pairing-ion in the mobile phase could provide a very simple way 
of achieving this. With the model compounds -and pairfing-ions tried 
(Chapter 3.5) no success was achieved in this research. The philosophy 
however is sound and has been illustrated to be feasible practically by 
Petterson (1981,1982 and 1983) using nonTaqueous solvent systems. The 
development of a wider range of optically active poiring-ions could 
spur major developments in this area. The reagents would need to 
possess a charged functional group suitable for ion-pairing, lipophilic 
properties, bulky functional groups or hydrogen bonding groups, all in 
close proximity to an asymmetric centre such that chiral recognition 
could take place. 
Concluding remarks 
Due to its enomous versatility ion-pair HPLC has proved 
invaluable as a tool for trace drug analysis. Hundreds of applications 
have appeared in the literature, and even. when the theoretical basis of 
separations is not understood practising analysts should find many more 
applications where IPC is the method of choice, for example the 
determination of inorganic ions. The major limitation of HPLC is still 
detection systems. Future developments, such as novel pairing-ions to 
overcome this problem, could still widen the scope of HPLC. Any such 
systems can only claim to have reached full potential when evaluated 
using a large number of 'real samples' rather than just standard 
solutions. 
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